Methods for local and systemic treatment of cancer, tumors, and tumor cells
Conjugates targeting CD25 with phthalocyanine dyes and light activation provide effective tumor cell death and immune enhancement, addressing the limitations of current cancer treatments by preserving IL-2 signaling and improving systemic immunity.
Patent Information
- Application Number
- JP2023546430
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-02-02
- Filing Date
- 2022-02-01
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-02-01
AI Technical Summary
Current treatments for cancer, particularly metastatic cancer, are inadequate in effectively targeting and eliminating both primary and secondary tumor cells while preserving immune function.
Conjugates comprising an antibody or antigen-binding fragment that binds to CD25 without interfering with IL-2 signaling, combined with a phthalocyanine dye, are activated by specific wavelengths of light to induce targeted cell death and enhance systemic immunity.
The conjugates achieve higher potency in tumor inhibition, reduce tumor growth, and enhance systemic immune responses, including in tumors resistant to conventional therapies, without disrupting IL-2 signaling or relying on Fc-mediated effector functions.
Smart Images

Figure 0007948938000033 
Figure 0007948938000034 
Figure 0007948938000035
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 144,931, filed on 2 February 2021, entitled “Methods for Local and Systemic Treatment of Cancers, Tumors and Tumor Cells,” the contents of which are incorporated in their entirety by reference.
[0002] Inclusion by referencing sequence listings This application is filed together with an electronic sequence listing. The sequence listing is provided as a 38.2-kilobyte file named 751702002240SeqList.txt, created on January 31, 2022. The electronic information of the sequence listing is incorporated in its entirety by reference.
[0003] field This disclosure relates to conjugates, compositions, methods and uses relating to treating subjects having cancer, for example, a first tumor, a primary tumor, metastatic tumor cells, and / or invasive tumor cells. The method comprises the steps of administering to a subject a targeting molecule that binds to the interleukin-2 receptor alpha chain (CD25) without substantially blocking or interfering with IL-2 signaling, wherein the targeting molecule is conjugated with a phthalocyanine dye such as IR700, and subsequently irradiating the first tumor or primary tumor with a wavelength of light to activate the phthalocyanine dye. The methods and uses described herein provide reduction and elimination of tumor and tumor cell growth, including the first tumor, a primary tumor, metastatic tumor cells, and / or invasive tumor cells. Methods and uses are also provided for enhancing systemic immunity against tumor growth in subjects having cancer, tumors, or lesions. [Background technology]
[0004] background Cancer metastasis is a leading cause of cancer-related death. Despite the availability of several treatment options for certain types of cancer, there is still an urgent need for effective treatment strategies to address cancers encompassing both primary and metastatic tumors. In particular, treating metastatic cancer remains a significant clinical challenge. [Overview of the project]
[0005] overview Compositions, combinations, methods and uses for treating cancer are provided herein. In some of the embodiments, a conjugate is provided comprising an antibody or antigen-binding fragment that specifically binds to CD25 without substantially blocking or interfering with IL-2 signaling, and a Si-phthalocyanine dye. In some of the embodiments, the conjugate is activated by irradiation at wavelengths from 600 nm or about 600 nm to 850 nm or about 850 nm to induce cell death. In some of the embodiments, the activated conjugate does not substantially block or interfere with IL-2 signaling. In some of the embodiments, the Si-phthalocyanine dye is IR700. In some of the embodiments, the Si-phthalocyanine dye is of formula (I): The structure TIFF0007948938000001.tif71128, or its salts, stereoisomers, or tautomers.
[0006] In some of the available embodiments, activated conjugates cause tumor inhibition or death at higher levels, activity, or potency than unconjugated antibodies.
[0007] Provided herein is a conjugate comprising an antibody or antigen-binding fragment that specifically binds to CD25 without substantially blocking or interfering with IL-2 signaling, and a Si-phthalocyanine dye, wherein the conjugate is activated by irradiation at a wavelength from 600 nm or about 600 nm to 850 nm or about 850 nm to cause cell death.
[0008] In some of any embodiments, the antibody or antigen-binding fragment comprises a heavy chain variable (V H ) region and a light chain variable (V L ) region. In some of any embodiments, the V H region comprises heavy chain complementarity determining region 1 (CDR-H1), heavy chain complementarity determining region 2 (CDR-H2) and heavy chain complementarity determining region 3 (CDR-H3) contained within the V H region amino acid sequence set forth in SEQ ID NO:1, and the V L region comprises light chain complementarity determining region 1 (CDR-L1), light chain complementarity determining region 2 (CDR-L2) and light chain complementarity determining region 3 (CDR-L3) contained within the V L region amino acid sequence set forth in SEQ ID NO:2. In some of any embodiments, the V H region comprises CDR-H1, CDR-H2 and CDR-H3 contained within the V H region amino acid sequence set forth in SEQ ID NO:3, and the V L region comprises CDR-L1, CDR-L2 and CDR-L3 contained within the V L region amino acid sequence set forth in SEQ ID NO:4. In some of any embodiments, the V H region comprises CDR-H1, CDR-H2 and CDR-H3 contained within the V H region amino acid sequence set forth in SEQ ID NO:5, and the V L region comprises CDR-L1, CDR-L2 and CDR-L3 contained within the V L region amino acid sequence set forth in SEQ ID NO:6.
[0009] In some of any embodiments, the V HThe region is V, indicated by SEQ ID NO:7. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:8. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:9. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:11. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:9. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:12. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:10. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:11. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:10. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:12. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:13. HIt contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:16. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:13. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:17. L It contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence.
[0010] In some of the arbitrary embodiments, V H The region is V, indicated by SEQ ID NO:13. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:18. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:13. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:19. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:14. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:16. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:14.H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:17. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:14. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:18. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:14. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:19. L It contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence.
[0011] In some of the arbitrary embodiments, V H The region is V, indicated by SEQ ID NO:15. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:16. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:15. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:17. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V HThe region is V, indicated by SEQ ID NO:15. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:18. L It contains CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence. In some of the embodiments, V H The region is V, indicated by SEQ ID NO:15. H It contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, V L The region is V, indicated by SEQ ID NO:19. L It contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence.
[0012] In some of the arbitrary embodiments, V H The region includes heavy chain complementarity determination region 1 (CDR-H1) containing the amino acid sequence shown in SEQ ID NO:20, heavy chain complementarity determination region 2 (CDR-H2) containing the amino acid sequence shown in SEQ ID NO:21, and heavy chain complementarity determination region 3 (CDR-H3) containing the amino acid sequence shown in SEQ ID NO:22. L The region includes light chain complementarity determination region 1 (CDR-L1) containing the amino acid sequence shown in SEQ ID NO:23, light chain complementarity determination region 2 (CDR-L2) containing the amino acid sequence shown in SEQ ID NO:24, and light chain complementarity determination region 3 (CDR-L3) containing the amino acid sequence shown in SEQ ID NO:25.
[0013] In some of the arbitrary embodiments, V H The region includes CDR-H1 containing the amino acid sequence shown in SEQ ID NO:26, CDR-H2 containing the amino acid sequence shown in SEQ ID NO:27, and CDR-H3 containing the amino acid sequence shown in SEQ ID NO:28. Lregion comprises CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:29, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:24, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:30.
[0014] In some of any aspects, V H region comprises CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:31, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:32, and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:33, and V L region comprises CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:34, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:35, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:36. In some of any aspects, V H region comprises CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:37, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:38, and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:39, and V L region comprises CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:40, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:41, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:42.
[0015] In some of any aspects, the conjugate comprises an antibody or antigen-binding fragment comprising a heavy chain variable (V H ) region and a light chain variable (V L ) region. In some of any aspects, V H region comprises the amino acid sequence set forth in SEQ ID NO:1, and V L region comprises the amino acid sequence set forth in SEQ ID NO:2. In some of any aspects, V H region comprises the amino acid sequence set forth in SEQ ID NO:3, and V Lregion comprises the amino acid sequence set forth in SEQ ID NO:4. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:5, and V L region comprises the amino acid sequence set forth in SEQ ID NO:6. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:7, and V L region comprises the amino acid sequence set forth in SEQ ID NO:8. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:9, and V L region comprises the amino acid sequence set forth in SEQ ID NO:11. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:9, and V L region comprises the amino acid sequence set forth in SEQ ID NO:12. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:10, and V L region comprises the amino acid sequence set forth in SEQ ID NO:11. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:10, and V L region comprises the amino acid sequence set forth in SEQ ID NO:12. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:13, and V L region comprises the amino acid sequence set forth in SEQ ID NO:16. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:13, and V L region comprises the amino acid sequence set forth in SEQ ID NO:17. In some of any embodiments, V H region comprises the amino acid sequence set forth in SEQ ID NO:13, and V L region comprises the amino acid sequence set forth in SEQ ID NO:18. In some of any embodiments, V HThe region includes the amino acid sequence shown in SEQ ID NO:13, V L The region contains the amino acid sequence shown in SEQ ID NO:19. In some of the arbitrary embodiments, V H The region contains the amino acid sequence shown in SEQ ID NO:14, V L The region contains the amino acid sequence shown in SEQ ID NO:16. In some of the arbitrary embodiments, V H The region contains the amino acid sequence shown in SEQ ID NO:14, V L The region contains the amino acid sequence shown in SEQ ID NO:17. In some of the arbitrary embodiments, V H The region contains the amino acid sequence shown in SEQ ID NO:14, V L The region contains the amino acid sequence shown in SEQ ID NO:18. In some of the arbitrary embodiments, V H The region contains the amino acid sequence shown in SEQ ID NO:14, V L The region contains the amino acid sequence shown in SEQ ID NO:19. In some of the arbitrary embodiments, V H The region includes the amino acid sequence shown in SEQ ID NO:15, V L The region contains the amino acid sequence shown in SEQ ID NO:16. In some of the arbitrary embodiments, V H The region includes the amino acid sequence shown in SEQ ID NO:15, V L The region contains the amino acid sequence shown in SEQ ID NO:17. In some of the arbitrary embodiments, V H The region includes the amino acid sequence shown in SEQ ID NO:15, V L The region contains the amino acid sequence shown in SEQ ID NO:18. In some of the arbitrary embodiments, V H The region includes the amino acid sequence shown in SEQ ID NO:15, V L The region includes the amino acid sequence shown in SEQ ID NO:19.
[0016] In some of the embodiments, the antibody or antigen-binding fragment comprises MA251, 7G7B6 or its antigen-binding portion. In some of the embodiments, the antibody or antigen-binding fragment is a human antibody or human antigen-binding fragment, a chimeric antibody or chimeric antigen-binding fragment, or a humanized antibody or humanized antigen-binding fragment. In some of the embodiments, the conjugate comprises an IgG1 Fc region or IgG1 isotype, an IgG2 Fc region or IgG2 isotype, an IgG3 Fc region or IgG3 isotype, or an IgG4 Fc region or IgG4 isotype.
[0017] In some of the embodiments, the antibody or antibody-binding fragment includes an IgG1 Fc region or an IgG1 isotype. In some of the embodiments, the IgG1 Fc region does not exhibit enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) effector function.
[0018] In some of the arbitrary embodiments, the antibody or antibody-binding fragment comprises an IgG2 Fc region or an IgG2 isotype. In some of the arbitrary embodiments, the IgG2 Fc region comprises a substitution that reduces or suppresses ADCC effector function. In some of the arbitrary embodiments, the substitution is an asparagine-to-glutamine substitution (N297Q) in the Fc region at the position corresponding to 297 by EU numbering.
[0019] In some of the embodiments, the conjugate exhibits one or more Fc-mediated effector functions. In some of the embodiments, the conjugate lacks Fc-mediated effector function, exhibits substantially reduced Fc-mediated effector function, or exhibits substantially no Fc-mediated effector function. In some of the embodiments, the activated conjugate is capable of killing cells in the absence of substantially Fc-mediated effector function. In some of the embodiments, the Fc-mediated effector function is selected from one or more of antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cell-mediated cytotoxicity (CDC). In some of the embodiments, the antibody or antigen-binding fragment includes the Fc region of a human immunoglobulin and / or the human antibody framework region.
[0020] Methods for treating tumors or lesions in a subject are provided herein. In some of the available embodiments, the method provided comprises the steps of administering to a subject one of the conjugates provided herein; to a target site in the subject at a wavelength from 600 nm or about 600 nm to 850 nm or about 850 nm, and at 25 J / cm² 2 Alternatively, approximately 25 J / cm² 2 From 400 J / cm² 2 Alternatively, approximately 400 J / cm² 2 The process involves irradiating the fiber with doses ranging from 2 J / cm of fiber length or approximately 2 J / cm of fiber length to 500 J / cm of fiber length or approximately 500 J / cm of fiber length, thereby activating the conjugate.
[0021] A step of administering to a subject a conjugate containing an antibody or antigen-binding fragment that specifically binds to CD25 without substantially blocking or interfering with IL-2 signaling, and a Si-phthalocyanine dye; and delivering to a target site within the subject at a wavelength from 600 nm or approximately 600 nm to 850 nm or approximately 850 nm, at a rate of 25 J / cm². 2 Alternatively, approximately 25 J / cm² 2 From 400 J / cm² 2 Alternatively, approximately 400 J / cm² 2A method for treating a tumor or lesion in a target is provided herein, comprising the step of irradiating with a dose of up to or from 2 J / cm of fiber length or about 2 J / cm of fiber length to 500 J / cm of fiber length or about 500 J / cm of fiber length, thereby activating the conjugate.
[0022] In some of the arbitrary embodiments, the Si-phthalocyanine dye is IR700, and irradiation is carried out at a wavelength of 690 nm ± 20 nm.
[0023] In some of the arbitrary embodiments, the Si-phthalocyanine dye is of formula (I) The material contains TIFF0007948938000002.tif71128, or its salts, stereoisomers, or tautomers, and irradiation is performed at a wavelength of 660 nm ± 50 nm.
[0024] In some of the various embodiments, the growth, volume, or dimensions of the tumor or lesion are reduced or inhibited.
[0025] In some of the embodiments, the tumor or lesion being treated, or the tumor microenvironment (TME) of the tumor or lesion being treated, contains reduced levels of immune effector cells. In some of the embodiments, the tumor or lesion has a reduced response to or is unresponsive to non-conjugate antibodies.
[0026] In some of the arbitrary embodiments, the immune effector cells are selected from one or more of macrophages, natural killer (NK) cells, neutrophils, and eosinophils.
[0027] In some of the embodiments, the target site is irradiated within approximately 24 ± 4 hours after administration of the conjugate. In some of the embodiments, the target site is irradiated at 50 mW / cm². 2 Alternatively, approximately 50 mW / cm² 2 From 200mW / cm² 2 Alternatively, approximately 200 mW / cm² 2The target area is irradiated with an optical power ranging from 100 mW / cm of fiber length or approximately 100 mW / cm of fiber length to 500 mW / cm of fiber length or approximately 500 mW / cm of fiber length. In some of the arbitrary embodiments, the target area is irradiated for a period of 120 seconds or approximately 120 seconds to 600 seconds or approximately 600 seconds.
[0028] In some of the various aspects, the tumor or lesion is resistant to or unresponsive to immune checkpoint inhibitor therapy.
[0029] In some of the various embodiments, the conjugate includes an IgG1 Fc region or IgG1 isotype, an IgG2 Fc region or IgG2 isotype, an IgG3 Fc region or IgG3 isotype, or an IgG4 Fc region or IgG4 isotype.
[0030] In some of the embodiments, the antibody or antibody-conjugated fragment includes an IgG1 Fc region or an IgG1 isotype. In some of the embodiments, the IgG1 Fc region is not enhanced with respect to ADCC effector function. In some of the embodiments, the antibody or antibody-conjugated fragment includes an IgG2 Fc region or an IgG2 isotype. In some of the embodiments, the IgG2 Fc region includes a substitution that reduces or suppresses ADCC effector function. In some of the embodiments, the substitution is an asparagine-to-glutamine substitution (N297Q) in the Fc region at the position corresponding to 297 by EU numbering.
[0031] In some of the embodiments, the conjugate exhibits one or more Fc-mediated effector functions. In some of the embodiments, the conjugate lacks Fc-mediated effector function, exhibits substantially reduced Fc-mediated effector function, or exhibits substantially no Fc-mediated effector function. In some of the embodiments, the activated conjugate is capable of killing cells in the absence of substantially Fc-mediated effector function. In some of the embodiments, the Fc-mediated effector function is selected from one or more of antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cell-mediated cytotoxicity (CDC).
[0032] In some of the embodiments, the methods disclosed herein further involve the step of administering an immune checkpoint inhibitor therapy after the administration of a conjugate. In some of the embodiments, the immune checkpoint inhibitor therapy is administered 1, 2, 3, 4, 5, 6, 7, 1 week, 2 weeks, or 3 weeks after the administration of the conjugate. In some of the embodiments, the immune checkpoint inhibitor therapy is administered 1, 2, 3, 4, 5, 6, 7, 1 week, 2 weeks, or 3 weeks after irradiation. In some of the embodiments, the immune checkpoint inhibitor therapy is administered more than once after the administration of the conjugate.
[0033] In some of the embodiments, immune checkpoint inhibitor therapy includes PD-1 inhibitors, PD-L1 inhibitors, or CTLA-4 inhibitors. In some of the embodiments, PD-1 inhibitors include pembrolizumab (MK-3475, KEYTRUDA; lambrolizumab), nivolumab (OPDIVO), semiprimab (LIBTAYO), tripalimab (JS001), HX008, SG001, GLS-010, dostallimab (TSR-042), tislerizumab (BGB-A317), and cetrelimab (JNJ-6372). 3283), Pizilizumab (CT-011), Genolimuzumab (APL-501, GB226), BCD-100, Semiprimab (REGN2810), F520, Syntilimab (IBI308), CS1003, LZM009, Camrelizumab (SHR-1210), SCT-I10A, MGA012, AK105, PF-06801591, AMP-224, AB122, AMG The anti-PD-1 antibody is selected from 404, BI 754091, HLX10, JTX-4014, AMP-514 (MEDI0680), Sym021, MGD019, MGD013, AK104, XmAb20717, RO7121661, CX-188, spartalizumab, BCD-217, HX009, IBI308, PDR001, REGN2810, TSR-042 (ANB011), or their antigen-binding fragments or any combination thereof.
[0034] In some of the various embodiments, the population of regulatory T cells (Tregs) in the tumor or lesion or in the tumor microenvironment is reduced as a result of the method.
[0035] In some of the arbitrary embodiments, reduction or inhibition includes an increase of less than 20% in tumor volume or tumor dimensions, or one or more of a reduction in tumor volume, tumor dimensions or tumor mass, or a reduction in the number of tumor cells. In some of the arbitrary embodiments, tumor or lesion growth, volume or dimensions are inhibited or reduced to a greater extent compared to a method using a conjugate comprising an antibody or antigen-binding fragment that specifically binds to CD25 and substantially blocks or interferes with IL-2 signaling.
[0036] In some of the embodiments, the methods disclosed herein improve the overall survival of the subject. In some of the embodiments, the subject has a second tumor or secondary population of tumor cells, and the growth, volume or size of the second tumor or secondary population of tumor cells is reduced or inhibited as a result of the method. In some of the embodiments, the second tumor or secondary population of tumor cells is not irradiated or has never been irradiated. [Brief explanation of the drawing]
[0037] [Figure 1] Figure 1 shows the mean tumor volume over time in mice with transplanted CT26 tumors. Mice were administered either an exemplary IL-2 non-blocking anti-CD25-mIgG1-IR700 conjugate (7D4-IR700; triangle) or an exemplary IL-2 blocking anti-CD25-IgG1-IR700 conjugate (PC61-IR700; square) alone (solid line), or conjugated and then irradiated at 690 nm with a dose of 100 J / cm2 (dashed line). Control tumor-bearing mice were administered only with saline (white circle). [Figure 2] Figures 2A–2E show tumor growth in individual mice from Figure 1. [Figure 3] Figure 3 shows the survival of the mice from Figure 1. [Figure 4]Figure 4A shows the mean tumor volume over time in mice with transplanted MCA205 mouse fibrosarcoma. Mice were administered anti-PD1 antibody (white circles, dashed line), exemplary IL-2 non-blocking anti-CD25 antibody (7D4-mIgG2a; black square, solid line), or exemplary IL-2 blocking anti-CD25 antibody and anti-PD-1 antibody combination (7D4-mIgG2a+a-PD1; white square, dashed line). Control tumor-bearing mice were administered only saline (black circles, solid line). Figure 4B shows the mean tumor volume over time in mice with transplanted MCA205 mouse fibrosarcoma. Mice were administered either an anti-PD1 antibody (white circles, dashed line), irradiation at 690 nm at a dose of 200 J / cm² after an exemplary IL-2 non-blocking anti-CD25-mIgG1-IR700 conjugate (7D4-mIgG2a-IR700+PIT; black triangles, solid line), or a combination of irradiation at 690 nm at a dose of 200 J / cm² after an exemplary IL-2 non-blocking anti-CD25-mIgG1-IR700 conjugate and an anti-PD-1 antibody (7D4-mIgG2a-IR700 PIT+a-PD1; white triangles, dashed line). Control tumor-bearing mice were administered only with physiological saline (black circles, solid line). [Figure 5] Figures 5A-5F show tumor growth in individual mice compared to Figures 4A-4B. [Figure 6] Figure 6 shows the survival of mice from Figures 4A to 4B. [Figure 7] Figure 7A shows the antitumor effects of irradiated tumors in mice with bilaterally transplanted MCA205 mouse fibrosarcoma using saline (white triangles, dashed lines), an exemplary IL-2 blocking anti-CD25-IR700 conjugate alone (PC61-IR700; white circles, solid lines), or irradiation at a dose of 200 J / cm2 at 690 nm after conjugation (PC61-IR700 PIT; black circles, solid lines). Figure 7B shows the antitumor effects of irradiated tumors in mice with bilaterally transplanted MCA205 mouse fibrosarcoma using saline (white triangles, dashed lines), an exemplary IL-2 non-blocking anti-CD25-IR700 conjugate alone (7D4-IR700; white squares, solid lines), or irradiation at a dose of 200 J / cm2 at 690 nm after conjugation (black squares, solid lines). [Figure 8] Figure 8A shows the antitumor effects of saline (white triangle, dashed line), exemplary IL-2 blocking anti-CD25-IR700 conjugate alone (PC61-IR700; white circle, solid line), or irradiation at a dose of 200 J / cm2 at 690 nm after conjugate (PC61-IR700 PIT; black circle, solid line) in non-irradiated distal tumors of mice from Figure 7A. Figure 8B shows the antitumor effects of saline (white triangle, dashed line), exemplary IL-2 non-blocking anti-CD25-IR700 conjugate alone (7D4-IR700; white square, solid line), or irradiation at a dose of 200 J / cm2 at 690 nm after conjugate (black square, solid line) in non-irradiated distal tumors of mice from Figure 7B. [Figure 9] Figure 9 shows the antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the IL-2 non-blocking anti-CD25 antibody (7D4-mIgG2a) and the corresponding IR700 conjugate (7D4-mIgG2a-IR700). [Figure 10] Figure 10 shows the mean tumor volume over time in mice with transplanted CT26 tumors. Mice were administered either an exemplary IL-2 non-blocking antibody with a mouse IgG2a skeleton (7D4-mIgG2a; black square), the corresponding ADCC / ADCP null IL-2 non-blocking antibody (7D4-mIgG2a-N297Q; white square), or an exemplary IL-2 non-blocking anti-CD25-mIgG1-IR700 conjugate with a mouse IgG1 skeleton alone (7D4-mIgG1-IR700; triangle), or irradiation at a dose of 100 J / cm2 at 690 nm after the conjugate (7D4-mIgG1-IR700+PIT, dashed line). Control tumor-bearing mice were administered only with saline (white circles). [Figure 11] Figures 11A–11E show tumor growth in individual mice from Figure 10. [Figure 12] Figure 12 shows the survival of the mice from Figure 10. [Figure 13]Figure 13 shows the mean tumor volume over time in mice with transplanted immunological "cold" tumors. Mice were administered either an exemplary IL-2 non-blocking antibody with a mouse IgG2a skeleton (7D4-mIgG2a) alone (white square) or in combination with an anti-PD-1 antibody (black square), or irradiation alone at a dose of 150 J / cm2 at 690 nm after the corresponding exemplary IL-2 non-blocking anti-CD25-mIgG1-IR700 conjugate (7D4-mIgG1-IR700 PIT; white triangle) or in combination with an anti-PD-1 antibody (black triangle). Control tumor-bearing mice were administered either saline alone (white circle) or anti-PD-1 alone (black circle). [Figure 14] Figure 14 shows the survival of the mouse from Figure 13. [Modes for carrying out the invention]
[0038] Detailed explanation This specification provides conjugates, compositions, combinations and methods for treating cancer, including cancers that include not only a primary tumor or primary tumor or multiple primary tumors but also a secondary population of tumor cells that have been introduced later, such as metastatic tumor cells, e.g., metastatic cancer; and / or cancers that include not only a primary tumor or multiple primary tumors but also invasive or infiltrative tumor cells, e.g., invasive cancer or infiltrative cancer. Also provided are conjugates, compositions, combinations and methods for enhancing systemic immunity in subjects having cancer, such as invasive cancer, infiltrative cancer, or metastatic cancer. Also provided are conjugates, compositions, combinations and methods for generating an enhanced response, such as an enhanced response to treatment or therapy in subjects having cancer or tumors, such as invasive cancer, infiltrative cancer, or metastatic cancer. In some situations, cancer exhibits reduced immune responsiveness (e.g., low levels or exhausted tumor-infiltrating lymphocytes (TILs), insufficient tumor antigen loading, and / or an immunosuppressive microenvironment; also known as a “cold” tumor), and the conjugates, compositions, combinations, and / or methods provided result in treatment of the cancer, enhancing the systemic immunity of the subject and / or generating an enhanced response to treatment or therapy in the subject.
[0039] In any of the embodiments provided, the conjugates described herein may exhibit one or more mechanisms of antitumor effect. Thus, the conjugates provided herein present the ability to provide antitumor effects across a broader spectrum of tumor types and tumor environments. The conjugates herein target the CD25 antigen on the cell surface and therefore can specifically target CD25-expressing T cells for destruction in the manner provided. In some aspects, the conjugates can bind to the CD25 antigen but do not substantially block or interfere with IL-2 signaling. In some aspects, the preservation of IL-2 signaling not only enables the enhancement of stimulation and activation-induced cell death (AICD) of cytotoxic effector T cells but also promotes the differentiation of T cells into effector T cells and memory T cells. In some aspects, the conjugates also include photoactivatable phthalocyanine dyes. The conjugated dyes enable the activation of targeted cell death in the presence of or irradiation with light of a specific wavelength. In some aspects, unlike non-conjugated anti-CD25 antibodies, targeted destruction of CD25-expressing T cells can be localized using light delivery. In addition, conjugates can provide targeted cell death in the absence of Fc-mediated effector function. Therefore, in some aspects, conjugates provide cell death in tumors and tumor microenvironments where antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and complement-dependent cell-mediated cytotoxicity (CDC) are reduced or inhibited.
[0040] The conjugates, compositions, combinations, methods, and uses provided can be used to treat cancers including primary tumors, metastatic tumor cells, and / or invasive tumor cells. In some embodiments, phthalocyanine dyes conjugated with CD25-binding targeting molecules are used alone or in combination with immune checkpoint inhibitors. The methods and uses described herein offer various advantages, including the elimination of the need to locate and / or directly irradiate metastatic and / or invasive tumor cells in the treatment of cancers, e.g., cancers including secondary populations of tumor cells, metastatic cancers, and / or invasive cancers. The disclosure also offers an unexpected feature of enhancing systemic immunity in the subject, e.g., against cancer recurrence.
[0041] The embodiments provided include or use a targeting molecule such as an IL-2 non-blocking anti-CD25 targeting antibody or its antigen-binding fragment (e.g., also called an IL-2 non-blocking antibody) that specifically binds to CD25 but does not interfere with or block the binding of IL-2 to CD25, for example, substantially interferes with or substantially blocks it. The embodiments provided include or use an IL-2 non-blocking anti-CD25 conjugate, such as a conjugate comprising an IL-2 non-blocking anti-CD25 targeting antibody or its antigen-binding fragment and a phthalocyanine dye having a silicon-coordinate metal (Si-phthalocyanine dye). In any embodiment, the phthalocyanine dye is its salt or ionic form. In any embodiment, the phthalocyanine dye is its salt, ionic form, stereoisomer, or tautomer.
[0042] CD25, also known as the alpha chain of the interleukin-2 receptor (IL-2Ra or IL-2Rα), is constitutively highly expressed on regulatory T cells (Tregs) and activated T cells. In some cases, CD25 can also be expressed on cancer cells, for example, on leukemic cells in some acute myeloid leukemias. IL-2 plays a vital role in its primary function during immunohomeostasis, particularly through its direct effects on regulatory T cells and the optimization and fine-tuning of effector lymphocyte responses (Arenas-Ramirez et al., (2015) Trends Immunol. 36(12):763-777). For example, in the thymus where T cells mature, low levels of IL-2 signaling can promote the differentiation of certain immature T cells into Tregs, while high levels of IL-2 signaling can stimulate cytotoxic effector T cells that can promote antitumor responses. IL-2 can also enhance activation-induced cell death (AICD). If early T cells are also stimulated by an antigen, IL-2 signaling can also promote the differentiation of T cells into effector T cells and memory T cells (Liao et al., (2011) Curr Opin Immunol. 23(5):598-604). IL-2 expression and secretion are tightly regulated and function as part of both transient positive and negative feedback loops in initiating and attenuating immune responses. Due to its role in the development of T cell immunological memory, which depends on the expansion of the number and function of antigen-selective T cell clones, it plays a major role in conferring cellular immunity. Therefore, in the embodiments provided, IL-2 non-blocking anti-CD25 antibodies or conjugates do not interfere with, for example substantially, these contributions of IL-2 to the immune response. In some embodiments, the methods and uses provided do not systemically interfere with or block IL-2 signaling outside the irradiated tumor or lesion, for example substantially.
[0043] In any of the embodiments provided, the conjugate described herein may exhibit one or more Fc-mediated effector functions. Fc-mediated effector functions include, but are not limited to, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and complement-dependent cell-mediated cytotoxicity (CDC). In some embodiments, an Fc-mediated effector function (e.g., ADCC or ADCP) can be induced in CD25-expressing cells when bound to an IL-2 non-blocking anti-CD25 antibody conjugate provided herein. In some embodiments, the IL-2 non-blocking anti-CD25 antibody includes a functional Fc region to enable the Fc-mediated effector function (e.g., ADCC or ADCP) of the IL-2 non-blocking anti-CD25 conjugate provided herein.
[0044] In some embodiments, the IL-2 non-blocking anti-CD25 antibody contains an Fc region modified to enhance one or more Fc-mediated effector functions (e.g., ADCC and / or ADCP) of the provided IL-2 non-blocking anti-CD25 conjugate. Exemplary modifications to the Fc region include substitution of one or more amino acids within the Fc region and / or the entire Fc region with the Fc region of a different isotype antibody. In such embodiments, the provided method causes targeted elimination of CD25-expressing cells via irradiation and, via the Fc-mediated effector function (e.g., ADCC or ADCP), for example, ADCC-mediated elimination of CD25-expressing cells distal to the irradiation site, while also preserving and / or not substantially interfering with IL-2 signaling.
[0045] In some embodiments, the Fc region of an IL-2 non-blocking anti-CD25 antibody is non-functional or has reduced Fc-mediated effector function, e.g., reduced ADCC, ADCP, and / or CDC activity. In some such embodiments, the Fc region of a targeting antibody is modified to reduce or eliminate Fc-mediated effector function (e.g., ADCC and / or ADCP). Such modifications include partial or complete amino acid substitutions, deletions, or shortenings of the Fc region.
[0046] The embodiments provided are based on the observation that, in some situations, cancer treatment using a phthalocyanine dye-targeting molecule conjugate, such as an IL-2 non-blocking anti-CD25 antibody-phthalocyanine dye conjugate (e.g., IL-2 non-blocking anti-CD25-IR700), followed by irradiation of a first tumor or primary tumor, results not only in the treatment of the irradiated tumor, e.g., the irradiated first tumor or irradiated primary tumor, but also in the effective treatment of tumors distal to the irradiation site (e.g., metastatic tumors), and in the effective treatment of tumors introduced after the subject has achieved complete remission following treatment of the initial tumor, exhibiting a tumor-specific immunomemory response. The embodiments provided are based on further observations that combination therapy using an IL-2 non-blocking anti-CD25 antibody-phthalocyanine dye conjugate (e.g., IL-2 non-blocking anti-CD25-IR700) and an immune checkpoint inhibitor such as an anti-PD-1 antibody results in significant synergistic effects in the treatment of both irradiated primary tumors and distal or subsequently introduced tumors, such as tumors including a secondary population of tumor cells, metastatic tumors, and / or invasive tumors.
[0047] The provided embodiments are based, in some instances, on the observation that treatment of tumors with an IL-2 non-blocking anti-CD25 conjugate (e.g., an IL-2 non-blocking anti-CD25-IR700) exhibits at least two modes of action to cause targeted cell killing. In some instances, the tumor is a tumor such as a "cold" tumor, which has reduced immunoreactivity (e.g., exhibits low levels of and exhausted tumor-infiltrating lymphocytes (TILs), insufficient tumor antigen load, and / or an immunosuppressive microenvironment). In some instances, tumors with reduced immunoreactivity do not respond, or do not substantially respond, to immune checkpoint inhibitor therapy, such as one or more of anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy. Accordingly, the provided conjugates, compositions, combinations, methods and uses have been demonstrated to provide a substantially improved and effective treatment of cancer, including not only a first tumor or primary tumor or multiple primary tumors, but also cancer comprising metastatic tumor cells, e.g., metastatic cancer; and / or cancer comprising not only a first tumor or primary tumor or multiple primary tumors, but also invasive tumor cells, e.g., invasive cancer. The provided conjugates, compositions, combinations, methods and uses can result in enhancement or improvement of a systemic immune response against cancer, including a subject's immune response, e.g., an immune memory response that can be effective against tumors, which can develop after treatment.
[0048] The methods and uses provided herein include the steps of treating a subject having one or more first tumors, e.g., a primary tumor, and optionally a secondary population of cells, e.g., metastatic tumor cells and / or invasive tumor cells, with a conjugate comprising a phthalocyanine dye linked to a targeting molecule, such as a targeting molecule that binds to CD25; and after administration of the conjugate, irradiating the one or more first tumors or primary tumors with a light wavelength suitable for use with the phthalocyanine dye. Some embodiments of the methods include the step of administering an immune checkpoint inhibitor before, concurrently with, or after administration of the conjugate.
[0049] I. Method and use of treatment with IL-2 non-blocking anti-CD25 conjugate In some embodiments, the methods and uses provided involve administering an anti-CD25 conjugate, such as a conjugate containing an anti-CD25 antibody (i.e., an IL-2 non-blocking anti-CD25 antibody) and a phthalocyanine dye, which, when the antibody is bound, does not substantially block IL-2 access to or binding to CD25, or substantially interfere with or impair IL-2-mediated signaling via CD25; and irradiating a target region with a wavelength of light suitable for use with the phthalocyanine dye, thereby exciting the dye and causing the death of cells expressing CD25 on its surface.
[0050] In some aspects, IL-2 non-blocking anti-CD25 conjugates are provided. In such embodiments, IL-2 is capable of binding to CD25, while the anti-CD25 conjugate also binds to CD25, and IL-2-mediated signal transduction via binding to CD25 is not impaired in cells within or distal to the irradiated target region. IL-2-mediated activities include expansion of cytotoxic T lymphocytes and other immunomodulatory activities, such as those described in Ross and Cantrell (2018) Annu Rev Immunol. 36: 411-433. Such methods enhance, activate, induce, elicit, increase or support immune functions such as local and / or systemic immunity, reduce or eliminate lesions (e.g., tumors), reduce or inhibit tumor growth, reduce, inhibit or eliminate metastasis of tumor cells, or provide any combination thereof. In some embodiments, the provided methods and uses result in the treatment or management of cancers, including cancers that comprise not only a first tumor or multiple tumors (e.g., one or more primary tumors), but also secondary populations of cancer cells such as metastatic tumor cells (e.g., metastatic cancer), invasive tumor cells (e.g., invasive cancer), or infiltrative tumor cells (e.g., infiltrative cancer). In some embodiments, the secondary population of cancer cells is, for example, directly or indirectly related to the first tumor. In some embodiments, the secondary population of cells is not directly derived from the first tumor.
[0051] The methods and uses provided include therapeutic methods and uses, for example, therapeutic methods and uses involving the administration of a conjugate to a subject having cancer and subsequent irradiation (or radiation) of cancer-related tumors (such as a first tumor) or the tumor microenvironment using specific wavelengths and doses of light. In some aspects, the irradiation (or radiation) results in irradiation-dependent lysis and death of cells expressing CD25 target molecules, resulting in a therapeutic effect or treatment of cancer (in some cases referred to as photoimmunotherapy (PIT)). In some aspects, the method also involves the step of administering an immunomodulator, such as an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody), in combination with the phthalocyanine dye-targeting molecule conjugate. In some aspects, the combination of the phthalocyanine dye-targeting molecule conjugate and an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody) is used, for example, as a combination therapy or combination treatment in the methods and uses provided, for example, in the methods and uses provided for the treatment of cancer.
[0052] Uses include the use of compositions and combinations described herein in such methods and procedures, and the use of such compositions and combinations in the preparation of pharmaceuticals for performing such therapeutic methods. In some aspects, such therapeutic methods include combination therapies. In some aspects, the methods and uses thereby treat cancers in a subject, e.g., a first tumor (which is primary or non-primary) and a secondary population of one or more tumor cells (e.g., metastatic tumor cells and / or invasive tumor cells), e.g., tumors and cancers including metastatic and / or invasive cancers. In some aspects, the secondary tumor cells are related to the first tumor. In some aspects of the methods and uses, one or more tumors are treated. In some aspects, methods and uses of such conjugates, compositions and combinations are also provided in enhancing, elevating, increasing, strengthening, increasing, boosting or supporting immune functions such as systemic immunity in a subject.
[0053] The method comprises administering to a subject having a first tumor a conjugate comprising a phthalocyanine dye linked to a targeting molecule, wherein the targeting molecule binds to CD25; and, after administration of the conjugate, irradiating at least the first tumor with a wavelength of light suitable for the selected phthalocyanine dye. In some embodiments, the method includes administering an immune checkpoint inhibitor, such as an anti-PD-1 antibody, before, simultaneously with, or after administration of the conjugate. In some embodiments, the method further administers an additional therapeutic agent or anticancer treatment.
[0054] In some embodiments, the method involves irradiating a tumor or tumor microenvironment (TME) associated with cancer, or cells present in the TME, with light. In some aspects, the tumor or TME is irradiated with a wavelength of light suitable for treatment or procedure. In some embodiments, the wavelength of light suitable for use with phthalocyanine dyes includes light having a wavelength that achieves activation of the dye-conjugate by irradiation with absorbent light, thereby exciting the photosensitizer and resulting in cell death, which in turn reduces or eliminates a lesion (e.g., a tumor), reduces or inhibits tumor growth, reduces, inhibits or eliminates a secondary population of tumor cells such as tumor cell metastases, or reduces, inhibits or eliminates invasive and / or metastatic tumor cells, or any combination thereof.
[0055] In some embodiments, the irradiation is at wavelengths of approximately 500 nm to 900 nm, approximately 600 nm to 850 nm, approximately 650 nm to 800 nm, or approximately 660 nm to 740 nm. In some embodiments, the irradiation is at wavelengths of 690 ± 50 nm, 690 ± 20 nm, or approximately 690 ± 20 nm.
[0056] The irradiation should be at least 1 J / cm². 2 Alternatively, irradiation can be performed at a dose of 1 J / fiber length cm. In some embodiments, the lesion may be irradiated at a dose of 2 J / cm 2 Alternatively, approximately 2 J / cm 2 From 400 J / cm² 2Alternatively, approximately 400 J / cm² 2 The irradiation is performed at doses ranging from 2 J / cm of fiber length or approximately 2 J / cm of fiber length to 500 J / cm of fiber length or approximately 500 J / cm of fiber length. In some embodiments, the irradiation is at least 2 J / cm 2 , 5J / cm 2 , 10J / cm 2 , 25J / cm 2 50 J / cm 2 75 J / cm 2 , 100 J / cm 2 , 150 J / cm 2 , 200 J / cm 2 300 J / cm² 2 , 400 J / cm 2 , or 500 J / cm² 2 Or at least about 2 J / cm 2 , 5J / cm 2 , 10J / cm 2 , 25J / cm 2 50 J / cm 2 75 J / cm 2 , 100 J / cm 2 , 150 J / cm 2 , 200 J / cm 2 300 J / cm² 2 , 400 J / cm 2 , or 500 J / cm² 2 The irradiation is at a dose of; or the lesion is irradiated with a dose of at least 2 J / fiber length cm, 5 J / fiber length cm, 10 J / fiber length cm, 25 J / fiber length cm, 50 J / fiber length cm, 75 J / fiber length cm, 100 J / fiber length cm, 150 J / fiber length cm, 200 J / fiber length cm, 250 J / fiber length cm, 300 J / fiber length cm, 400 J / fiber length cm or 500 J / fiber length cm, or at least about 2 J / fiber length cm, 5 J / fiber length cm, 10 J / fiber length cm, 25 J / fiber length cm, 50 J / fiber length cm, 75 J / fiber length cm, 100 J / fiber length cm, 150 J / fiber length cm, 200 J / fiber length cm, 250 J / fiber length cm, 300 J / fiber length cm, 400 J / fiber length cm or 500 J / fiber length cm.
[0057] In some embodiments, the irradiation is approximately 25 J / cm². 2 From approximately 400 J / cm² 2 The irradiation dose is up to or from approximately 2 J / cm of fiber length to approximately 500 J / cm of fiber length. In some embodiments, the irradiation dose is 5 J / cm 2 From 200 J / cm² 2 The irradiation dose is up to or from 20 J / cm of fiber length to 500 J / cm of fiber length. In some embodiments, the irradiation dose is approximately 50 J / cm 2 Alternatively, irradiation is performed at a dose of 100 J / cm of fiber length.
[0058] In some aspects of the methods and uses provided herein, the optical power (or optical fluence) of the light ranges from 20 J / fiber length cm or about 20 J / fiber length cm to 500 J / fiber length cm or about 500 J / fiber length cm. In some aspects, the optical power (or optical fluence) of the interstitial light dose ranges from 100 mW / fiber length cm or about 100 mW / fiber length cm to 500 mW / fiber length cm or about 500 mW / fiber length cm. In some aspects, the light is applied for a period of 120 seconds or about 120 seconds to 600 seconds or about 600 seconds. In some aspects, the irradiation is performed for 250 seconds or about 250 seconds at a dose of 100 J / fiber length cm or about 100 J / fiber length cm with an optical fluence of 400 mW / cm or about 400 mW / cm.
[0059] In some aspects of the methods and uses provided herein, the optical power (or optical fluence) of the light is 25 J / cm². 2 Or approximately 25 J / cm 2 From 400 J / cm² 2 Or approximately 400 J / cm² 2 Up to 50 mW / cm². In some embodiments, the optical power (or optical fluence) of the light dose is 50 mW / cm². 2 Or approximately 50 mW / cm² 2 From 200mW / cm² 2 Or approximately 200 mW / cm²2 Up to [a certain point]. In some embodiments, the light is applied for a period of 120 seconds or about 120 seconds to 600 seconds or about 600 seconds. In some embodiments, the irradiation is 50 J / cm². 2 Or approximately 50 J / cm² 2 At this dose, 150 mW / cm² 2 It is performed with optical power for 333 seconds or approximately 333 seconds.
[0060] In some embodiments of the methods and uses provided herein, irradiation is performed after administration of a phthalocyanine dye-targeting molecule conjugate (e.g., IL-2 non-blocking anti-CD25 antibody-IR700 conjugate). In some embodiments, irradiation or irradiation is performed or accomplished 30 minutes to 96 hours or about 30 minutes to 96 hours after administration of the phthalocyanine dye-targeting molecule conjugate, for example, 30 minutes to 48 hours, 30 minutes to 24 hours or 12 hours to 48 hours after administration of the conjugate, for example, generally at least 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours or more after administration of the conjugate. In some embodiments, irradiation is performed within approximately 24 hours after administration of the conjugate, or within 24 hours ± 4 hours after administration of the conjugate, or within approximately 20, 21, 22, 23, 24, 24, 26, 27, or 28 hours after administration of the conjugate.
[0061] The methods described herein include the step of irradiating a first tumor in a subject, such as a primary tumor, or the tumor microenvironment (TME) of the first tumor. In some embodiments, the methods and uses provided herein include the step of treating a subject having one or more tumors. A subject may have one, two, three, or more than three tumors. Such tumors may be located in one or more tissues or organs, for example, in one tissue or organ, in two different tissues or organs, in three different tissues or organs, or in three or more different tissues or organs.
[0062] In some aspects, the primary tumor may refer to the first tumor or primordial tumor in the subject, but may also refer to one or more tumors selected for irradiation by the methods and uses provided herein. In some embodiments, the first tumor or further tumor may be one or more solid tumors, a lymphoma, or a leukemia. The tumor may be of the lung, stomach, liver, pancreas, breast, esophagus, head and neck, brain, peripheral nerves, skin, small intestine, colon, rectum, anus, ovary, uterus, bladder, prostate, adipose tissue, skeletal muscle, smooth muscle, blood vessels, bone, bone marrow, eye, tongue, lymph node, spleen, kidney, cervix, male genitalia, female genitalia, testes, or a tumor of unknown primary origin.
[0063] In some embodiments of the method, the growth of a first tumor or primary tumor is inhibited, the volume of one or more primary tumors is reduced, or both tumor growth and volume are reduced. In some embodiments of the method, the growth of a first tumor or primary tumor is inhibited, the volume of one or more primary tumors is reduced, or both tumor growth and volume are reduced compared to monotherapy such as administration of conjugate alone, conjugate and subsequent irradiation alone, or anti-PD-1 antibody alone.
[0064] In some embodiments, the methods and uses provided herein include the step of treating a subject having one or more tumors and also a secondary population of tumor cells, such as invasive tumor cells. In some such embodiments, the secondary population includes cases where cells arising from a tumor, such as a primary tumor, have invaded surrounding tissue. The method includes administering to a subject having a first tumor and invasive tumor cells a conjugate comprising a phthalocyanine dye linked to a targeting molecule, wherein the targeting molecule binds to CD25; and, after administration of the conjugate, irradiating the first tumor with a wavelength suitable for the selected phthalocyanine dye. In some such embodiments, the secondary population of tumor cells is not directly irradiated. In some embodiments, the method includes the step of administering an immune checkpoint inhibitor before, simultaneously with, or after administration of the conjugate. In some embodiments, the method includes administering an anti-PD-1 antibody before, simultaneously with, or subsequently to the administration of an IL-2 non-blocking anti-CD25 antibody-IR700 conjugate, followed by irradiation of a first tumor.
[0065] In some aspects, invasive tumor cells refer to cells arising from a primary tumor that invade the surrounding tissue of the same organ or adjacent organs of the primary tumor in the subject having the first tumor. In some aspects, the first tumor is the primary tumor, and the invasive tumor cells originate directly or indirectly from the first tumor. In some aspects, the invasive tumor cells do not originate directly from the first tumor.
[0066] The methods and uses provided herein involve irradiation of a first tumor and / or further tumors, without irradiating some or all of the invasive tumor cells. In some embodiments, the growth of invasive tumor cells is inhibited, reduced, or eliminated, resulting in a reduction in the volume, dimensions, or mass of one or more invasive tumors, or any combination thereof. In some embodiments, along with the effect on one or more invasive tumor cells, the growth of the first tumor is also inhibited, reduced, or eliminated, and the volume, dimensions, or mass of the first tumor or further tumors is also reduced.
[0067] In some embodiments, invasive tumor cells are contained within a solid tumor. In some embodiments, invasive tumor cells are contained within a fluid that includes, but is not limited to, peritoneal fluid, pleural fluid, and cerebrospinal fluid. In some embodiments, invasive tumor cells are contained within the exudate of one or more body cavities that includes, but is not limited to, peritoneal exudate (ascites), pleural exudate, and pericardial exudate.
[0068] In some embodiments, the methods and uses provided herein include a step of treating a subject having a first tumor and a secondary population of tumor cells, such as invasive and / or metastatic tumor cells (e.g., a secondary population of associated tumor cells). The method includes administering to the subject having the first tumor and a secondary population of tumor cells, such as invasive and / or metastatic tumor cells (e.g., a secondary population of associated tumor cells), a conjugate comprising a phthalocyanine dye linked to a targeting molecule, wherein the targeting molecule is bound to CD25; and, after administration of the conjugate, irradiating the first tumor with a wavelength suitable for the selected phthalocyanine dye. In some such embodiments, the secondary population of tumor cells is not directly irradiated. In some embodiments, the method includes administering an immune checkpoint inhibitor, such as an anti-PD-1 antibody, before, simultaneously with, or after administration of the conjugate. In such a manner, the growth (volume, dimensions, or mass) of a secondary population of tumor cells, such as a primary tumor and / or metastatic tumor cells, is inhibited, reduced, or eliminated, resulting in a reduction in the volume, dimensions, or mass of one or more of the primary tumor and / or secondary cell populations, or any combination thereof. In some embodiments, the inhibition of the primary tumor and / or secondary populations is achieved to a greater extent than the inhibition achieved by administration of conjugate alone, conjugate and subsequent irradiation alone, or anti-PD-1 antibody alone. In some embodiments, inhibition is achieved when the tumor shows an increase of less than 20% in tumor volume, tumor dimensions, or tumor mass; when there is no change in tumor volume, dimensions, or mass (i.e., halted tumor growth or progression); when the tumor is reduced in terms of volume, dimensions, or mass; or when there is a reduction in the number of tumor cells. In some aspects, the reduction in tumor volume, tumor dimensions, or tumor mass, or the number of tumor cells, includes a reduction of 30% or more or about 30% or more.
[0069] In any of the methods and uses described herein, the first tumor may be a primary tumor or a secondary tumor. In some embodiments, the first tumor and the secondary population of tumor cells are related. In some embodiments, the secondary cell population is directly or indirectly derived from the first tumor. In some embodiments, the secondary population is not derived from the first tumor. In some embodiments, the first tumor is a primary tumor and the secondary cell population is related to the primary tumor; for example, the secondary cell population is directly or indirectly derived from the primary tumor. In some embodiments, the first tumor is a primary tumor and the secondary population of tumor cells is a secondary primary tumor. In some embodiments, the first tumor is a secondary tumor and the secondary cell population is related to the secondary tumor. In some aspects, the secondary population of tumors includes cells that originate from the primary tumor and invade proximal or distal healthy tissue (i.e., invasive tumor cells), or cells that spread to one or more distal tissues or organs within the body of the subject with the primary tumor, for example, tissues or organs located far from or adjacent to the primary tumor (i.e., metastatic tumor cells). In some aspects, the secondary population of tumor cells is both invasive and metastatic. In some aspects, the secondary population of tumor cells is invasive. In some aspects, the secondary population of tumor cells is metastatic and directly or indirectly related to the first tumor, e.g., originating from it. In other aspects, the secondary population of tumor cells is metastatic and not directly related to the first tumor. Metastatic tumor cells may be located in one or more locations in the lungs, stomach, liver, pancreas, breast, esophagus, head and neck, brain, peripheral nerves, skin, small intestine, colon, rectum, anus, ovaries, uterus, bladder, prostate, adipose tissue, skeletal muscle, smooth muscle, blood vessels, bone, bone marrow, eyes, tongue, lymph nodes, spleen, kidneys, cervix, male reproductive organs, female reproductive organs, testes, blood, bone marrow, cerebrospinal fluid, or any other tissue or organ. In some embodiments, metastatic tumor cells are contained within a solid tumor. In some embodiments, metastatic tumor cells are circulating tumor cells, humoral tumors, or unrelated to a tumor mass.
[0070] In some embodiments of the methods and uses provided herein, the secondary tumor cells are metastatic tumor cells that are distal to the first tumor, and some or all of the metastatic tumor cells are not irradiated, for example, not directly irradiated. In some embodiments of the methods and uses, after administration of the conjugate, only the first tumor is irradiated, and invasive or metastatic tumor cells are not directly irradiated. In some embodiments, more than one tumor, including the first tumor, is irradiated, but at least one site of tumor cells, such as a site containing metastatic tumor cells, is not irradiated.
[0071] II. Methods for enhancing systemic immunity and / or response Also provided herein are methods and uses of the compositions and combinations in enhancing, increasing, augmenting or supporting immune functions such as systemic immunity in a subject, for example, a subject having cancer or a tumor. In some embodiments, the methods and uses herein comprise the step of enhancing systemic immunity in a subject having a cancer, tumor or cancerous lesion. In some aspects, "systemic immunity" refers to the ability of a subject's immune system to respond systemically to immunological challenges, including those associated with cancer or tumors. In some aspects, systemic immunity can include a systemic response of the subject's adaptive immune system and / or innate immune system. In some aspects, systemic immunity comprises an immune response across various tissues including the bloodstream, lymph nodes, bone marrow, spleen and / or tumor microenvironment, and in some cases, comprises a coordinated response between tissues and organs as well as various cells and factors of the tissues and organs. Also provided herein are methods and uses of the compositions and combinations in enhancing, increasing or augmenting the response to a procedure or therapy in a subject, for example, a subject having cancer or a tumor.
[0072] In some aspects, the methods and uses provided herein include administering to a subject a conjugate comprising a phthalocyanine dye linked to a targeting molecule, wherein the targeting molecule binds to CD25 without blocking, for example substantially blocking, IL-2 binding or signaling; administering an immune checkpoint inhibitor; and irradiating the tumor or cancerous lesion or tumor microenvironment after administration of the conjugate. Irradiation conditions, such as wavelength, dose of irradiation, and timing of irradiation, are, for example, described herein. The immune checkpoint inhibitor may be administered before, simultaneously with, or subsequently to the administration of the conjugate, as described herein. In some aspects, the methods and uses provided herein may result in enhancement of systemic immunity in the subject, which may then result in an enhanced or synergistic response to cancer treatment or procedure. In some aspects, the methods and uses provided herein result in an enhanced response, such as a synergistic response, to the treatment or therapy of cancer or tumors compared to the administration of the conjugate alone, the conjugate and subsequent irradiation alone, or the anti-PD-1 antibody alone. In some aspects, the enhanced response includes an enhancement of the subject's systemic immunity compared to the subject's systemic immunity before the administration of the conjugate and subsequent irradiation and the anti-PD-1 antibody. In some aspects, the enhanced response includes an enhanced response to the treatment, such as an additional, additive or synergistic response, and / or a more complete response, a more persistent response or a longer-lasting response, compared to the administration of the conjugate alone, the conjugate and subsequent irradiation alone, or the anti-PD-1 antibody alone.
[0073] In some aspects of the methods and uses provided herein, systemic immunity against recurrent tumors is increased or amplified. In some aspects, the level, intensity, or extent of systemic immunity is increased by intratumor CD8 + T lymphocyte count, CD8 + T lymphocytes and regulatory T cells (T reg) ratio, intratumor T lymphocyte exhaustion (e.g., CD3 expressing PD-1 and / or CTLA4 markers) + CD8 + (percentage of cells), intratumor-activated CD8 + The number or percentage of T lymphocytes (e.g., CD45) + Ki67 as a percentage of cells + or CD69 + (CD8 cells), cytotoxic intratumor T lymphocyte expansion based on cytotoxicity of splenocytes against tumor cells (e.g., CD3 cells that do not express PD-1 and / or CTLA4 markers) + CD8 + It can be measured based on the percentage of cells, or any combination or all of them. In some aspects, intratumoral CD8 + T lymphocytes, exhausted tumor T lymphocytes, activated CD8 + T lymphocytes, or T lymphocytes within an enlarged cytotoxic tumor, are leukocytes (CD45 + (cells) and / or total CD8 + T cells (e.g., CD3 + CD8 + CD45 + It is measured as a percentage of cells. The determination of such a number or percentage can be achieved using several well-known methods, including those described herein. For example, such a number or percentage can be determined by generating a single-cell suspension, such as by mechanical dissociation of a collection of tumor and / or tissue biopsy or blood sample containing circulating immune cells, followed by staining and flow cytometry analysis or mass cytometry. Other methods may include multiplexed immunofluorescence imaging of tissue and / or tumor biopsy.
[0074] In some such embodiments, the intensity or range of immunity is compared to the intensity or range of immunity in the same subject before treatment. In some such embodiments, the intensity or range of immunity is compared to a population of subjects. In some such embodiments, the intensity or range of immunity is compared to a threshold. In some embodiments, the intensity or range of immunity after combination therapy, such as the combined administration of an IL-2 non-blocking anti-CD25 PIT (e.g., including photoirradiation for conjugate activation) and a checkpoint inhibitor (e.g., an anti-PD-1 antibody), is compared to the intensity or range of immunity after monotherapy, such as the administration of an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody) or an IL-2 blocking or non-blocking anti-CD25 conjugate or an IL-2 blocking or non-blocking anti-CD25 PIT alone.
[0075] In some embodiments, procedures following the methods and uses provided herein lead to the death or reduction in the number of regulatory T cells (Tregs), such as intratumoral CD4+ FoxP3+ Tregs. Thus, in some embodiments, the level, intensity, or extent of systemic immunity is reduced, affecting intratumoral or circulating regulatory T cells (Tregs). reg ) can be measured based on the number or proportion. In some cases, the binding of an IL-2 non-blocking anti-CD25 conjugate to the surface of CD25-expressing cells, such as certain Tregs, and irradiation to achieve irradiation-dependent lysis and death of CD25-expressing cells results in a reduction in the number of CD25-expressing cells. In some cases, such results can lead to a reduction in the number of immunosuppressive cells, such as Tregs, within the tumor, and consequently, the mitigation or regression of immunosuppression in the tumor. In some cases, such a reduction in immunosuppressive cells can lead to the activation and proliferation of intratumor T cells, such as intratumor CD8+ cytotoxic T cells or CD4+ helper T cells, which can eliminate tumor cells and lead to a reduction in tumor volume and / or elimination of the tumor. In some cases, treatment according to the provided embodiments can lead to a reduction in intratumor Tregs and / or an increase in the intratumor CD8+ to Treg ratio or intratumor CD4+ to Treg ratio.
[0076] In some aspects, treatments following the methods and uses provided herein can result in a sustained or permanent decrease in intratumor Tregs. In some aspects, treatments following the methods and uses provided herein can result in a sustained or permanent increase in the ratio of intratumor CD8+ to Tregs or intratumor CD4+ to Tregs. In some aspects, the level, intensity, or extent of systemic immunity is affected by intratumor CD8 + It can be measured by determining the ratio of Tregs to intratumor CD8 + If the ratio of Tregs increases after treatment compared to before treatment, then systemic immunity against recurrent tumors is increased or amplified. In some embodiments, the level, intensity, or extent of systemic immunity is related to intratumor CD4 + It can be measured by determining the ratio of Tregs to intratumor CD4 + If the ratio of Tregs to Tregs increases after treatment compared to before treatment, then systemic immunity against recurrent tumors is increased or amplified. In some embodiments, the level, intensity, or extent of systemic immunity is determined by the ratio of intratumor Tregs to CD45 + It can be measured by determining the ratio of intratumor Treg and CD45 + If the ratio decreases after treatment compared to before treatment, then systemic immunity against recurrent tumors is increased or enhanced. In some cases, such an increase or decrease can last for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or 3, 4, 5, 6, 7, or 8 weeks or longer, or approximately 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or 3, 4, 5, 6, 7, or 8 weeks or longer.
[0077] In some aspects, the level, intensity, or extent of systemic immunity can be measured by CTL activity assays using spleen cells, peripheral blood cells, bone marrow cells, or lymph node cells. In some embodiments, cells are collected from subjects between 4 and 28 days after irradiation of the first tumor in the subject.
[0078] In some aspects, the level, intensity, or extent of systemic immunity can be measured by an intratumor T cell exhaustion assay using T cells collected from the primary tumor or metastatic tumor cell mass or invasive tumor cell mass. In some embodiments, cells are collected from the subject between 4 and 28 days after irradiation of the primary tumor in the subject.
[0079] In some aspects, the level, intensity, or extent of systemic immunity can be measured by an intratumor effector T cell proliferation assay using T cells collected from the primary tumor or metastatic tumor cell mass or invasive tumor cell mass. In some embodiments, cells are collected from the subject between 4 and 28 days after irradiation of the primary tumor in the subject.
[0080] In some aspects, the level, intensity, or extent of systemic immunity can be measured by a T cell receptor diversity assay using T cells collected from the primary tumor or metastatic tumor cell mass or invasive tumor cell mass or peripheral circulation. In some embodiments, cells are collected from the subject between 4 and 28 days after irradiation of the primary tumor in the subject.
[0081] In some aspects, the level, intensity, or extent of systemic immunity can be measured by determining the presence, number, or frequency of regulatory T cells (Tregs) in the tumor from the primary tumor or metastatic tumor cell mass or invasive tumor cell mass, and / or the ratio of intratumoral Treg cells to intratumoral CD8+ T cells or intratumoral CD4+ T cells. In some embodiments, cells are collected from the subject between 4 and 28 days after irradiation of the primary tumor in the subject.
[0082] In some embodiments, any of the above assays can be used in combination.
[0083] III. Conjugates and compositions for use with this method In some aspects, compositions and combinations are provided that include a conjugate containing a phthalocyanine dye linked to a targeting molecule, for example, a conjugate containing a phthalocyanine dye linked to a targeting molecule, such as an antibody or its antigen-binding fragment, which binds to the CD25 protein but does not block, for example substantially block, the binding of IL-2 to CD25. In some aspects, the compositions or combinations provided include an immune checkpoint inhibitor, such as an anti-PD-1 antibody. In some aspects, conjugates, compositions and combinations are provided for use in treatment methods or treatment regimens according to the methods and uses provided, or in the manufacture of pharmaceuticals for the treatment of cancer or tumors. In some aspects, the treatment includes a combination treatment. In some aspects, compositions and combinations are provided for use according to the methods and uses provided.
[0084] The methods and uses provided herein utilize a conjugate comprising a targeting molecule that binds to CD25, for example, an anti-CD25 antibody or antigen-binding fragment (i.e., an IL-2 non-blocking anti-CD25 antibody) that binds to CD25, for example, specifically but does not block IL-2 from also binding to CD25, for example substantially, and / or does not interfere with IL-2-mediated signaling via interaction with CD25, for example substantially. CD25 can be expressed on CD8+ cells, activated T cells including CD4+ FoxP3+ regulatory T cells, activated B cells, some thymocytes, myeloid progenitor cells, and oligodendrocytes. CD25 is also known as interleukin-2 receptor alpha chain (IL2RA), IDDM10, IL2R, TCGFR, p55, or IMD41.
[0085] In some contexts, “IL-2 non-blocking antibody” or “IL-2 non-blocking anti-CD25 antibody” includes an anti-CD25 antibody (e.g., an anti-CD25 IL-2 non-blocking antibody) that can specifically bind to the CD25 subunit of the IL-2 receptor without blocking the binding of IL-2 to CD25 or IL-2 signaling via CD25. In some contexts, an IL-2 non-blocking anti-CD25 antibody enables IL-2 signaling in response to IL-2 binding to CD25 at a rate of at least 50% compared to the signaling level in the absence of the anti-CD25 antibody. In some contexts, an IL-2 non-blocking anti-CD25 antibody enables IL-2 signaling in response to IL-2 binding to CD25 at a rate of at least 75% compared to the signaling level in the absence of the anti-CD25 antibody.
[0086] In some contexts, "IL-2 non-blocking," which may be related to "non-blocking," "not blocking," or grammatical variations thereof, and which may be related to the non-blocking of IL-2 binding to CD25 in the presence of an anti-CD25 antibody, includes cases where the anti-CD25 antibody or antigen-binding fragment inhibits IL-2 signaling by less than 50% compared to IL-2 signaling in the absence of the antibody. In some contexts, the anti-CD25 antibody or antigen-binding fragment inhibits IL-2 signaling by about 40%, 35%, 30%, e.g., less than 25%, compared to IL-2 signaling in the absence of the anti-CD25 antibody. An IL-2 non-blocking anti-CD25 antibody can bind to CD25 without interfering with IL-2 binding to CD25, or substantially without interfering with IL-2 binding to CD25. In some contexts, IL-2 non-blocking anti-CD25 antibodies are alternatively referred to as "anti-CD25 antibodies that do not inhibit the binding of interleukin-2 to CD25," or "anti-CD25 antibodies that do not inhibit IL-2 signaling," or "antibodies or antigen-binding fragments that specifically bind to CD25 without substantially blocking or interfering with IL-2 signaling."
[0087] In some aspects, some anti-CD25 antibodies may enable IL-2 to bind to CD25, but still block CD25 receptor-mediated signaling. In some aspects, such antibodies are not considered IL-2 non-blocking. In some embodiments, IL-2 non-blocking anti-CD25 antibodies enable IL-2 to bind to CD25, thereby promoting CD25 receptor-mediated signaling at a level of at least 50% compared to signaling in the absence of the IL-2 non-blocking anti-CD25 antibody.
[0088] In some aspects, CD25-mediated IL-2 signaling can be evaluated or measured by any known method for evaluating or measuring cellular signaling, such as phosphorylation assays, binding assays, reporter assays, T cell activation assays, in vitro effector assays, in vitro antibody-dependent cell-mediated cytotoxicity assays (ADCC assays), in vitro antibody-dependent cell phagocytosis (ADCP), cytokine secretion assays, targeted cell death assays, or model animal experiments. In some aspects, exemplary methods for evaluating CD25-mediated IL-2 signaling include, for example, Rubin et al. (1985) Hybridoma 4(2) 91-102, Van Assche et al., Gut. 2006 Nov; 55(11): 1568-1574; Martin et al., J Immunol July 15, 2010, 185 (2) This includes, but is not limited to, any of the entries listed in 1311-1320, WO2019175223, WO2019175220, WO2019175222, WO2019175224, WO2019175216, WO2019175217, WO2019175226, WO2019175215, US10745485, US20210047420, US10738125, US20210009703, US20210040221, US20210009704, US20200407454, and US20210009699. In some cases, comparisons of IL-2 signaling in the presence and absence of anti-CD25 antibodies can be performed under the same or substantially the same conditions.
[0089] In some embodiments, IL-2 signaling can be determined by measuring the level of phosphorylated STAT5 protein in cells using a standard STAT5 phosphorylation assay. For example, a STAT5 phosphorylation assay for measuring IL-2 signaling may involve culturing PMBC cells in the presence of a specific concentration of anti-CD25 antibody, followed by the addition of various concentrations of IL-2 (e.g., serial dilutions of IL-2 concentration). The cells may then be permeabilized, and the level of STAT5 protein can be measured using a fluorescently labeled antibody against the phosphorylated STAT5 peptide analyzed by flow cytometry. The percentage of IL-2 signaling blocked can be calculated as follows: Blockade % = 100 × [STAT5 without antibody treatment] + Cell % - STAT5 with antibody treatment + %) / (STAT5 without antibody treatment) + cell%)].
[0090] In some embodiments, the targeting molecule can be any IL-2 non-blocking anti-CD25 antibody. Non-limiting and exemplary IL-2 non-blocking anti-CD25 antibodies can be, for example, variable heavy chain (V) antibodies according to Chothia numbering. H ), variable light chain (V L Table 1 lists the ), along with the SEQ ID NO corresponding to the amino acid sequence for the exemplary corresponding complementarity-determining region (CDR). In some embodiments, the targeting molecule is an IL-2 non-blocking anti-CD25 antibody or its antigen-binding fragment listed in Table 1. In some embodiments, the targeting molecule is an IL-2 non-blocking anti-CD25 antibody or antigen-binding fragment that competes with any one or more of the antibodies listed in Table 1 for the same or overlapping epitopes. In some embodiments, the targeting molecule is an IL-2 non-blocking anti-CD25 antibody or antigen-binding fragment that binds to an epitope that does not overlap with one or more of the antibodies listed in Table 1.
[0091] (Table 1) Sequence identifiers (SEQ ID NO) for exemplary anti-CD25 antibodies TIFF0007948938000003.tif114145
[0092] In some of the available embodiments, the targeting molecule is an antibody or an antigen-binding fragment thereof, or comprises an antigen-binding fragment. In some of the available embodiments, the antibody is an IL-2 non-blocking anti-CD25 antibody. In some of the available embodiments, the IL-2 non-blocking anti-CD25 antibody comprises a functional Fc region. In some of the available embodiments, the anti-CD25 antibody comprises a full-length Fc region. In some embodiments, the IL-2 non-blocking anti-CD25 antibody is an antibody fragment. In any of the available embodiments, the antibody or antibody fragment can be humanized by known methods. In some embodiments, the antibody or antibody fragment is a human antibody, a chimeric antibody, or a humanized antibody.
[0093] In some aspects of the embodiment, the IL-2 non-blocking anti-CD25 antibody is an antibody listed in Table 1, or its biosimilar, interconvertible, biobetter, copy biological product, or biogeneric, or a fragment thereof.
[0094] In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody or fragment thereof is listed in Table 1, for example, in each row of Table 1, V H and V L Antibodies containing V, including CDR-H1, CDR-H2, and CDR-H3 according to an antibody numbering scheme (e.g., Kabat, Chothia, Contact, IMGT, Aho, or AbM numbering scheme). H , and V including CDR-L1, CDR-L2, and CDR-L3 L This includes. In any one embodiment, the IL-2 non-blocking anti-CD25 antibody or fragment thereof includes CDR-H1, CDR-H2, and CDR-H3 of the antibodies listed in Table 1. H , and V including CDR-L1, CDR-L2, and CDR-L3 LThis includes. In some embodiments, the IL-2 non-blocking anti-CD25 antibody or fragment thereof includes CDR-H1, CDR-H2, and CDR-H3 of the antibodies listed in Table 1. H , as well as V, which includes antibodies CDR-L1, CDR-L2, and CDR-L3 listed in Table 1. L Includes. In some embodiments, the IL-2 non-blocking anti-CD25 antibody or a fragment thereof is V as indicated by the SEQ ID NO: listed in each row of Table 1 below. H and V L The region, or the V indicated by the SEQ ID NO: listed in each row of Table 1. H and V L V having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence. H and V L The antibody contains a sequence. In any one of the embodiments, the IL-2 non-blocking anti-CD25 antibody is, for example, the antibody listed in each row of Table 1. H and V L Each of the following V H and V L Includes.
[0095] In some of the embodiments provided, the exemplary IL-2 non-blocking anti-CD25 antibody conjugate comprises any known IL-2 non-blocking anti-CD25 antibody, its humanized form, and / or its antigen-binding fragment. In some aspects, the exemplary IL-2 non-blocking anti-CD25 antibody conjugate includes, for example, Rubin et al. (1985) Hybridoma 4(2) 91-102, Van Assche et al., Gut. 2006 Nov; 55(11): 1568-1574; Martin et al., J Immunol July 15, 2010, 185 (2) This includes, but is not limited to, any of the humanized forms and / or antigen-binding fragments described in 1311-1320, WO2019175223, WO2019175220, WO2019175222, WO2019175224, WO2019175216, WO2019175217, WO2019175226, WO2019175215, US10745485, US20210047420, US10738125, US20210009703, US20210040221, US20210009704, US20200407454, and US20210009699.
[0096] In some of the embodiments provided, the IL-2 non-blocking anti-CD25 antibody is 7G7B6 (Rubin et al. (1985) Hybridoma 4(2) 91-102), or a humanized 7G7B6 antibody, a fragment thereof, or derived from 7G7B6. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is 7G7B6 containing an Fc region, or its humanized form (humanized 7G7B6). In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is 7G7B6 or humanized 7G7B6 containing an Fc region that exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) activity or is engineered to exhibit enhanced ADCC activity. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is 7G7B6 or humanized 7G7B6 containing a full-length Fc region. In some embodiments, the IL-2 non-blocking anti-CD25 antibody is 7G7B6 or humanized 7G7B6 containing an Fc region that exhibits ADCC activity or enhanced ADCC activity. In some embodiments, the IL-2 non-blocking anti-CD25 antibody is 7G7B6 or humanized 7G7B6 containing an Fc region that exhibits no ADCC activity, substantially no ADCC activity, or reduced ADCC activity.
[0097] In some of the embodiments provided, the IL-2 non-blocking anti-CD25 antibody is MA251 (see, e.g., Van Assche et al., Gut. 2006 Nov; 55(11): 1568-1574; Martin et al., J Immunol July 15, 2010, 185 (2) 1311-1320), or its humanized form (humanized MA251), a fragment thereof, or derived from MA251. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is MA251 or humanized MA251 containing an Fc region. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is MA251 or humanized MA251 containing an Fc region that exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) activity or enhanced ADCC activity. In some embodiments, the IL-2 non-blocking anti-CD25 antibody is MA251 or humanized MA251 containing a full-length Fc region. In some embodiments, the IL-2 non-blocking anti-CD25 antibody is MA251 or humanized MA251 containing an Fc region that exhibits ADCC activity or enhanced ADCC activity. In some embodiments, the IL-2 non-blocking anti-CD25 antibody is MA251 or humanized MA251 containing an Fc region that exhibits no ADCC activity, substantially no ADCC activity, or reduced ADCC activity.
[0098] In some of the embodiments provided, the IL-2 non-blocking anti-CD25 antibody is "Clone A" (listed in Table 1) or a fragment thereof, or derived from "Clone A". In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is Clone A containing an Fc region. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is Clone A containing an Fc region engineered to exhibit antibody-dependent cell-mediated cytotoxicity (ADCC) activity or enhanced ADCC activity. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is Clone A containing a full-length Fc region. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is Clone A containing an Fc region engineered to exhibit ADCC activity or enhanced ADCC activity. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is Clone A containing an Fc region exhibiting no ADCC activity, substantial ADCC activity, or reduced ADCC activity.
[0099] In some of the embodiments provided, the IL-2 non-blocking anti-CD25 antibody is "Clone B" (listed in Table 1) or a fragment thereof, or derived from "Clone B". In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is "Clone B" containing an Fc region. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is "Clone B" containing an Fc region engineered to exhibit antibody-dependent cell-mediated cytotoxicity (ADCC) activity or enhanced ADCC activity. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is "Clone B" containing a full-length Fc region. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is "Clone B" containing an Fc region engineered to exhibit ADCC activity or enhanced ADCC activity. In some of the embodiments, the IL-2 non-blocking anti-CD25 antibody is "Clone B" containing an Fc region exhibiting no ADCC activity, substantial ADCC activity, or reduced ADCC activity.
[0100] In some embodiments, the targeting molecule may be an antibody or antibody fragment containing a “complementarity-determining region” or “CDR” of an IL-2 non-blocking anti-CD25 antibody, such as any of the antibodies or their antigen-binding fragments listed in Table 1. The CDR is typically responsible for binding to the antigen's epitope. The precise amino acid sequence boundary of a given CDR can be readily determined using one of several well-known schemes. Exemplary numbering schemes include the Kabat, Chothia, Contact, IMGT, Aho, and AbM numbering schemes. The boundary of a given CDR may vary depending on the scheme used specifically. For example, the Kabat scheme is based on structural alignment, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based on the most common antibody region sequence length, insertions are indicated by insertion letters, e.g., “30a”, and deletions appear in some antibodies. The two schemes place certain insertions and deletions ("indels") at different locations, resulting in differential numbering. The Contact scheme is based on the analysis of the composite crystal structure and is similar in many ways to the Chothia numbering scheme. The AbM scheme is a compromise between the Kabat and Chothia definitions, based on those used by Oxford Molecular's AbM antibody modeling software. Any antibody numbering scheme can be used to identify the CDR region of the antibodies and conjugates described herein and can be used in the methods and uses provided.
[0101] The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also generally identified by the chain on which a particular CDR is located. Thus, the heavy chain variable region (V H CDR3 (also called CDR-H3) is located in the variable domain of the heavy chain of the antibody in which it is found, whereas in the light chain variable region (V LCDR1 (also called CDR-L1) is a CDR1 found in the variable domain of the light chain of the antibody. Antibodies with different specificities, such as different binding sites for different antigens, have different CDRs. While CDRs vary among antibodies, only a limited number of amino acid positions within a CDR are directly involved in antigen binding. These positions within a CDR are called specificity-determining residues (SDRs). In some embodiments, the targeting molecule contains CDRs from 7G7B6, MA251, or "clone A" or "clone B," such as those listed in Table 1 according to the Chothia numbering scheme. In some embodiments, the targeting molecule contains CDRs from 7G7B6, MA251, or "clone A" or "clone B," according to a different numbering scheme. In some embodiments, the conjugate antibody is a biosimilar, interconvertible, or biobetter of any of the anti-CD25 antibodies described herein, e.g., 7G7B6, MA251, "Clone A," or "Clone B," or its antigen-binding fragment. Such antibodies also include copy biological products and biogenerics of any of the anti-CD25 antibodies described herein, or their antigen-binding fragments.
[0102] In some aspects of the methods and uses provided herein, the IL-2 non-blocking anti-CD25 antibody includes a functional Fc region. In some aspects of the methods and uses provided herein, the IL-2 non-blocking anti-CD25 antibody includes a full-length Fc region. In some aspects, the IL-2 non-blocking anti-CD25 antibody includes an IgG1 Fc region. In some aspects, the IL-2 non-blocking anti-CD25 antibody includes an IgG2 Fc region. In some aspects, the IgG2 Fc region is an IgG2a Fc region. In some aspects, the IgG2 Fc region is an IgG2a / b Fc region. In some aspects, the IgG2 Fc region is an IgG2a Fc region. In some aspects of the methods and uses provided herein, the IL-2 non-blocking anti-CD25 antibody includes an IgG3 Fc region. In some aspects of the methods and uses provided herein, the IL-2 non-blocking anti-CD25 antibody includes an IgG4 Fc region. In some embodiments, the Fc region is modified to modulate the effector function of the antibody portion of the conjugate. Any such modification, for example, those described in Wang et al., (2018) Protein Cell. 9(1): 63-73, is intended for the antibodies, antibody fragments, and conjugates described herein.
[0103] In some aspects of the methods and uses provided herein, the IL-2 non-blocking anti-CD25 antibody does not contain a functional Fc region. In some such examples, the IL-2 non-blocking antibody either does not contain an Fc region or contains an Fc region that has been modified so as not to bind to the Fc receptor and / or not to induce substantial Fc effector function (e.g., ADCC, ADCP, and / or CDC). In some such aspects, the IL-2 non-blocking antibody contains an Fc receptor containing an amino acid substitution to eliminate the glycosylation site at the position corresponding to position 297 of the heavy chain, based on the EU numbering described by Edelman et al., (1969) Proc Natl Acad Sci US A. 63(1):78-85. For example, an IL-2 non-blocking antibody may contain an Fc receptor with an asparagine-to-glutamine substitution at or corresponding to position 297 in the antibody sequence's EU numbering (N297Q), an asparagine-to-alanine substitution at or corresponding to position 297 in the antibody sequence's EU numbering (N297A), or an asparagine-to-glycine substitution at or corresponding to position 297 in the antibody sequence's EU numbering (N297G).
[0104] In some aspects of the methods and uses provided herein, the IL-2 non-blocking anti-CD25 antibody comprises an Fc region that exhibits enhanced Fc-mediated effector function, such as ADCC, ADCP, and / or CDC activity, and / or preferential binding to the Fc gamma receptor. In some aspects, the IL-2 non-blocking anti-CD25 antibody exhibits enhanced function due to increased association of the Fc receptor. In some embodiments, the Fc region contains one or more of the following mutations: a substitution of serine to aspartic acid at position 239 (S239D) with respect to the EU numbering of the antibody heavy chain, a substitution of alanine to leucine at position 330 (A330L), a substitution of isoleucine to glutamic acid at position 332 (I332E), a substitution of glutamic acid to alanine at position 333 (E333A), a substitution of lysine to alanine at position 334 (K334A), a substitution of arginine to alanine at position 255 (S255A), a substitution of threonine to alanine at position 256 (T256A), and at position 267 Substitutions include serine to alanine (S267A), serine to alanine at position 298 (S298A), asparagine to serine at position 325 (N325S), leucine to phenylalanine at position 328 (L328F), alanine to leucine at position 330 (A330L), isoleucine to glutamic acid at position 333 (E333A), glutamic acid to alanine at position 333 (E333A), lysine to alanine at position 334 (K334), and / or alanine to glutamine at position 378 (A378Q). In some embodiments, the Fc region contains serine to alanine at position 298 and lysine to alanine at position 334 (S298A / K334) with respect to the EU numbering of the antibody heavy chain. In some embodiments, the Fc region contains a substitution of glutamic acid to alanine at position 333 and a substitution of lysine to alanine at position 334 with respect to the EU numbering of the antibody heavy chain (E33A / K334). In some embodiments, the Fc region contains a substitution of arginine to alanine at position 255 and a substitution of serine to alanine at position 267 with respect to the EU numbering of the antibody heavy chain (R255A / S267A).In some embodiments, the Fc region contains a substitution of threonine to alanine at position 256 (T256A) with respect to the EU numbering of the antibody heavy chain. In some embodiments, the Fc region contains a substitution of lysine to alanine at position 334 and alanine to glutamine at position 378 (K334 / A378) with respect to the EU numbering of the antibody heavy chain. In some embodiments, the Fc region contains a substitution of serine to aspartic acid at position 239, alanine to leucine at position 330, and isoleucine to glutamic acid at position 332 (S239D / A330L / I332E) with respect to the EU numbering of the antibody heavy chain. In some embodiments, the Fc region contains a substitution of glycine to alanine at position 236, a substitution of serine to aspartic acid at position 239, and a substitution of isoleucine to glutamic acid at position 332 (S239D / A330L / I332E) with respect to the EU numbering of the antibody heavy chain. In some embodiments, the Fc region contains a substitution of arginine to serine at position 325 and a substitution of leucine to phenylalanine at position 328 (N325S / L328F) with respect to the EU numbering of the antibody heavy chain.
[0105] The methods and conjugates used herein contain phthalocyanine dyes. In some aspects of the methods and uses provided herein, the phthalocyanine dye is a phthalocyanine dye having a silicon-coordinating metal (Si-phthalocyanine dye). In any aspect, the phthalocyanine dye is a salt, stereoisomer, or tautomer of any of the dyes described herein. In any aspect, the phthalocyanine dye is an ionic form of any of the dyes described herein.
[0106] In some embodiments, phthalocyanine dyes are given by formula: Including TIFF0007948938000004.tif85128, in the formula, L is the linker; Q is a reactive group for the attachment of the dye to the targeting molecule; R 2 , R 3 , R 7, and R 8 Each is independently selected from optionally substituted alkyls and optionally substituted aryls; R 4 , R 5 , R 6 , R 9 , R 10 , and R 11 Each is independently selected from hydrogen, an optionally substituted alkyl, an optionally substituted alkanoyl, an optionally substituted alkoxycarbonyl, an optionally substituted alkylcarbamoyl, and a chelate ligand, where R 4 , R 5 , R 6 , R 9 , R 10 , and R 11 At least one of them contains a water-soluble group; R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 23 Each is independently selected from hydrogen, halogen, optionally substituted alkylthio, optionally substituted alkylamino and optionally substituted alkoxy; and X 2 and X 3 Each of these is independently of the C1-C atoms, which may have heteroatoms interposed in some cases. 10 It is alkylene.
[0107] In some embodiments, phthalocyanine dyes are given by formula: Includes TIFF0007948938000005.tif75137, in the formula, X 1 and X 4 Each of these is independently of the C1-C atoms, which may have heteroatoms interposed in some cases. 10 It is alkylene; R 2 , R3 , R 7 , and R 8 Each is independently selected from optionally substituted alkyls and optionally substituted aryls; R 4 , R 5 , R 6 , R 9 , R 10 , and R 11 Each is independently selected from hydrogen, an optionally substituted alkyl, an optionally substituted alkanoyl, an optionally substituted alkoxycarbonyl, an optionally substituted alkylcarbamoyl, and a chelate ligand, where R 4 , R 5 , R 6 , R 9 , R 10 , and R 11 At least one of them contains a water-soluble group; and R 16 , R 17 , R 18 and R 19 Each of these is independently selected from hydrogen, halogen, optionally substituted alkylthio, optionally substituted alkylamino, and optionally substituted alkoxy.
[0108] In some embodiments, the phthalocyanine dye is the Si-phthalocyanine dye IRDye 700DX (IR700). In some embodiments, the phthalocyanine dye containing the reactive group is the IR700 NHS ester, for example, the IRDye 700DX NHS ester (LiCor 929-70010, 929-70011). In some embodiments, the dye is given by the following formula: It is a compound containing TIFF0007948938000006.tif105159, or a salt thereof, ionic form, stereoisomer, or tautomer.
[0109] For the purposes of this specification, the terms "IR700," "IRDye 700," or "IRDye 700DX" include the above formula when the dye is conjugated to an antibody, for example, via a reactive group.
[0110] In some embodiments, the phthalocyanine dye is any dye described in International Publication No. 2021 / 207691. In some embodiments, the dye is a silicon phthalocyanine dye described in International Publication No. 2021 / 207691.
[0111] In some embodiments, phthalocyanine dyes are given by formula (X): TIFF0007948938000007.tif49128 or its salts, ionic forms, stereoisomers, or tautomers are included, in the formula, X is It is TIFF0007948938000008.tif22128; Y is It is TIFF0007948938000009.tif21128; R 1 and R 2 Each of these is independently a substituted alkyl, a substituted cycloalkyl, a substituted cycloalkylalkyl, a substituted heterocyclyl, a substituted heterocyclylalkyl, a substituted aryl, a substituted aralkyl, a substituted heteroaryl, or a substituted heteroaralkyl; R 3 , R 4 or R 5 is selected from substituent (a) or substituent (b), in which case, (a)R 3 is hydrogen, -L 3 -H, -L 3 -A or -L 3 -Z is; R 4 is, -L 4 -H, -(NH) m -L 4 -A, -(NH) m-L 4 -Z, -(O) m -L 4 -A or -(O) m -L 4 -Z is; R 5 is, -L 5 -H or -L 5 -A is; and (b)R 3 is, -L 3 -H or -L 3 -A is; R 4 is, -L 4 -H, -(NH) m -L 4 -A, or -(O) m -L 4 -A is the case; in that case, R 3 and R 4 It is connected by a bond, -L 4 -Forms heterocyclines substituted with A; and R 5 is, -L 5 -H or -L 5 -A is; However, R 3 , R 4 and R 5 At least one of them is a group containing A; A is a reactive group capable of forming a covalent bond with the thiol, hydroxyl, carboxyl, or amino group of the second part, or a protected form thereof, or a reactive form thereof; R 6 and R 7 Each of these is independently a substituted alkyl, a substituted cycloalkyl, a substituted cycloalkylalkyl, a substituted heterocyclyl, a substituted heterocyclylalkyl, a substituted aryl, a substituted aralkyl, a substituted heteroaryl, or a substituted heteroaralkyl; R 8 , R 9 or R 10 is selected from substituent (a) or substituent (b), in which case, (a)R8 is hydrogen, -L 8 -H or -L 8 -Z is; R 9 is, -L 9 -H, -(NH) n -L 9 -Z or -(O) n -L 9 -Z is; R 10 is, -L 10 -Z is; and (b)R 8 and R 9 It is connected by a bond, -L 9 -Z is substituted, forming a heterocycline, R 10 is, -L 10 -H or -L 10 -Z is; However, R 8 , R 9 and R 10 At least one of them is a group containing Z; Z is a water-soluble group that may be substituted with A or L'-A; L 1 and L 2 Each of these is independently an optionally substituted alkylene, an optionally substituted heteroalkylene, an optionally substituted alkenylene, an optionally substituted heteroalkenylene, an optionally substituted cycloalkyl, or an optionally substituted heterocycline; L 3 , L 4 , L 5 , L 8 , L 9 and L 10Each of these is independently a substituted alkylene, a substituted heteroalkylene, a substituted alkenylene, a substituted heteroalkenylene, a substituted cycloalkylene, a substituted heterocyclene, a substituted arylene, a substituted aralkylene, a substituted heteroaralkylene, or a substituted heteroarylene, where the carbon atoms of the alkylene, heteroalkylene, alkenylene, heteroarkenylene, cycloalkylene, heterocyclene, arylene, aralkylene, heteroaralkylene, or substituted heteroarylene may be further substituted with Z, and each nitrogen atom of the heteroalkylene or heteroalkenylene may be substituted with one or two L'-Z; L' is independently a substituted alkylene, a substituted heteroalkylene, a substituted alkenylene, a substituted heteroalkenylene, a substituted cycloalkylene, a substituted heterocyclene, a substituted arylene, a substituted aralkylene, a substituted heteroaralkylene, or a substituted heteroarylene; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; m is either 0 or 1; n is either 0 or 1; However, when b is 1, a is 0; When d is 1, then c is 0; When m is 1, then b is 1; When n is 1, then c is 1.
[0112] In a particular embodiment, the silicon phthalocyanine dye is given by the following formula: TIFF0007948938000010.tif152150TIFF0007948938000011.tif246134TIFF0007948938000012.tif206136, or selected from its salts, ionic forms, stereoisomers, or tautomers.
[0113] In a particular embodiment, the silicon phthalocyanine dye is given by the following formula: Selected from TIFF0007948938000013.tif111128 or its salts, ionic forms, stereoisomers, or tautomers.
[0114] In some embodiments, the dye is a silicon phthalocyanine dye selected from the compounds provided in Table A, or their salts, ionic forms, stereoisomers, or tautomers.
[0115] (Table A) TIFF0007948938000014.tif202164TIFF0007948938000015.tif213164TIFF00079489380 00016.tif222164TIFF0007948938000017.tif198164TIFF0007948938000018.tif104164
[0116] In certain embodiments, phthalocyanine dyes containing a reactive group are defined by formula (I): It has the structure of TIFF0007948938000019.tif72128.
[0117] In certain embodiments, phthalocyanine dyes containing a reactive group are defined by formula (II): It has the structure of TIFF0007948938000020.tif70128.
[0118] In some embodiments, the methods and compositions for use provided herein include a conjugate comprising a Si-phthalocyanine dye linked to a targeting molecule, wherein the targeting molecule is bound to CD25. In some embodiments, the targeting molecule is an IL-2 non-blocking anti-CD25 antibody or its antigen-binding fragment. In some embodiments, the composition comprises an IL-2 non-blocking anti-CD25-Si-phthalocyanine dye conjugate. In some embodiments, the composition comprises an IL-2 non-blocking anti-CD25-IR700 conjugate. In some embodiments, the composition comprises an IL-2 non-blocking anti-CD25-IR700 conjugate, wherein the anti-CD25 portion is 7G7B6, MA251, "clone A" or "clone B". In some embodiments, the composition comprises an IL-2 non-blocking anti-CD25-IR700 conjugate, wherein the IL-2 non-blocking anti-CD25 portion contains a functional Fc region. In some embodiments, the composition is an IL-2 nonblocking anti-CD25-IR700 conjugate, in which the IL-2 nonblocking anti-CD25 portion contains an Fc region, such as a full-length Fc region. In some embodiments, the composition is an IL-2 nonblocking anti-CD25-IR700 conjugate, in which the IL-2 nonblocking anti-CD25 portion contains an Fc region, such as an Fc region that exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) activity or is manipulated to exhibit enhanced ADCC activity.
[0119] IV. Combination therapy with checkpoint inhibitors The methods and uses provided herein may include the administration of an immune checkpoint inhibitor before, concurrently with, or after the administration of a conjugate. For example, the method may include the steps of administering one or more doses of an immune checkpoint inhibitor, administering a conjugate containing a phthalocyanine dye, such as a Si-phthalocyanine dye, linked to a targeting molecule, wherein the targeting molecule binds to CD25 without blocking IL-2, and irradiating a first tumor and optionally one or more further tumors after the administration of the conjugate. The method may also include the steps of first administering a conjugate containing a phthalocyanine dye linked to a targeting molecule, wherein the targeting molecule binds to CD25 without blocking IL-2, irradiating a first tumor and optionally one or more further tumors after the administration of the conjugate, and then administering an immune checkpoint inhibitor following either the administration of the conjugate or the irradiation (e.g., radiation) step. The method may also include the administration of an immune checkpoint inhibitor concurrently with the administration of the conjugate. In some cases, the combinations provided may include phthalocyanine dye-targeting molecule conjugates (e.g., IL-2 non-blocking anti-CD25 antibody-IR700 conjugate) and immune checkpoint inhibitors. In some cases, such combinations may be used in the methods or uses provided, such as in combination therapy or treatment.
[0120] In some embodiments, the immune checkpoint inhibitor is selected from PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, or combinations thereof. In some embodiments, the immune checkpoint inhibitor is selected from antibodies or antigen-binding fragments that bind to PD-1, antibodies or antigen-binding fragments that bind to PD-L1, or antibodies or antigen-binding fragments that bind to CTLA-4, or combinations thereof.
[0121] In some aspects of the methods and uses provided herein, the immune checkpoint inhibitor is an anti-PD-1 antibody. In some aspects, the anti-PD-1 antibody for use with the method is pembrolizumab (MK-3475, KEYTRUDA; lambrolizumab), nivolumab (OPDIVO), semiprimab (LIBTAYO), tripalimab (JS001), HX008, SG001, GLS-010, dostallimab (TSR-042), tislerizumab (BGB-A317), cetrelimab (JNJ -63723283), Pizilizumab (CT-011), Genolimuzumab (APL-501, GB226), BCD-100, Semiprimab (REGN2810), F520, Syntilimab (IBI308), CS1003, LZM009, Camrelizumab (SHR-1210), SCT-I10A, MGA012, AK105, PF-06801591, AMP-224, AB122, AMG This includes, but is not limited to, 404, BI 754091, HLX10, JTX-4014, AMP-514 (MEDI0680), Sym021, MGD019, MGD013, AK104, XmAb20717, RO7121661, CX-188, spartalizumab, BCD-217, HX009, IBI308, PDR001, REGN2810, TSR-042 (ANB011), or their antigen-binding fragments, or any combination thereof.
[0122] In some aspects of the methods and uses provided herein, the immune checkpoint inhibitor is an anti-PD-L1 antibody. Anti-PD-L1 antibodies that can be used in the methods and uses provided herein include atezolizumab (MPDL3280A, Tecentriq, RG7446), avelumab (BAVENCIO, MSB0010718C; M7824), durvalumab (MEDI4736, IMFINZI), LDP, NM-01, STI-3031 (IMC-001; STI-A1015), KN035, LY3300054, M7824 (MSB0011359C), BMS-936559, MSB2 This includes, but is not limited to, 311, BCD-135, BGB-A333, CBT-502 (TQB-2450), Kosiberimab (CK-301), CS1001 (WPB3155), FAZ053, MDX-1105, SHR-1316 (HTI-1088), TG-1501, ZKAB001 (STI-A1014), INBRX-105, MCLA-145, KN046, LY3415244, REGN3504, HLX20, or their antigen-binding fragments, or any combination thereof.
[0123] In some aspects of the methods and uses provided herein, the immune checkpoint inhibitor is an anti-CTLA-4 antibody. Exemplary anti-CTLA-4 antibodies include ipilimumab (YERVOY), tremelimumab (tisilimmumab, CP-675,206), AGEN1181, AGEN1884, ADU-1064, BCD-145, BCD-217, ADG116, AK104, ATOR-1015, BMS-986218, KN046, MGD019, MK-1308, REGN4659, XmAb20717, XmAb22841, or their antigen-binding fragments, or any combination thereof.
[0124] In some aspects of the methods and uses provided herein, the immune checkpoint inhibitor is selected from an antibody or antigen-binding fragment that binds to PD-1, PD-L1, or CTLA-4, and the conjugate is an IL-2 non-blocking anti-CD25-IR700 conjugate. In some aspects of the methods and uses provided herein, the immune checkpoint inhibitor is an antibody or antigen-binding fragment that binds to PD-1, and the conjugate is an IL-2 non-blocking anti-CD25-IR700 conjugate, where the IL-2 non-blocking anti-CD25 portion of the conjugate is 7G7B6 or derived therefrom, and the antibody portion of the conjugate includes a functional Fc region. In some embodiments of the method, the conjugate is an IL-2 nonblocking anti-CD25-IR700 conjugate, where the IL-2 nonblocking anti-CD25 portion of the conjugate is 7G7B6 containing a functional Fc region, derived from it, or competes with it. The anti-PD-1 antibody is pembrolizumab (MK-3475, KEYTRUDA), nivolumab (OPDIVO), or semiprimab (LIBTAYO), or their antigen-binding fragments.
[0125] In some aspects of the methods and uses provided herein, immune checkpoint inhibitors may be administered to subjects with cancer before the administration of an IL-2 non-blocking anti-CD25-Si phthalocyanine dye conjugate (e.g., an IL-2 non-blocking anti-CD25-IR700 conjugate), concurrently with the administration of an IL-2 non-blocking anti-CD25-Si phthalocyanine dye conjugate, after the administration of an IL-2 non-blocking anti-CD25-Si phthalocyanine dye conjugate, or in any combination thereof.
[0126] In some aspects of the methods and uses provided herein, an immune checkpoint inhibitor is administered to a subject one, two, three, four, five, six, seven, eight, nine, ten, or more than ten times.
[0127] In some embodiments, an immune checkpoint inhibitor is administered to the subject one, two, three, four, five, or more than five times prior to administration of the conjugate. In some embodiments, an immune checkpoint inhibitor is administered to the subject 12 hours, 24 hours, 48 hours, 96 hours, 1 week, 2 weeks, 3 weeks, or 4 weeks before administration of the conjugate, or approximately 12 hours, 24 hours, 48 hours, 96 hours, 1 week, 2 weeks, 3 weeks, or 4 weeks before administration. In some embodiments, an immune checkpoint inhibitor is administered to the subject less than 1 to 4 weeks, less than 1 to 3 weeks, or less than 1 to 2 weeks prior to administration of the conjugate.
[0128] In some embodiments, an immune checkpoint inhibitor is administered to the subject one, two, three, four, five, or more than five times after administration of the conjugate. In some embodiments, an immune checkpoint inhibitor is administered to the subject before and after administration of the conjugate.
[0129] In some embodiments of the methods and uses provided herein, an IL-2 non-blocking anti-CD25 conjugate is administered to a subject once or more than once. In some embodiments, the conjugate is administered to the subject once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times, or more than ten times. In some embodiments, the first tumor(s) is irradiated after each administration of the conjugate, for example, within 24 hours ± 4 hours after each administration of the conjugate. In some embodiments, if residual lesions such as the first tumor or one or more further tumors, residual cells or masses derived from the primary tumor, invasive cancer cells or metastatic tumor cells remain in the subject, the conjugate is administered more than once. In some embodiments, if residual lesions persist for a period of time longer than 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or more than 1 year after the prior administration of the conjugate, the administration of the conjugate is repeated.
[0130] In some aspects of the methods and uses provided herein, an IL-2 non-blocking anti-CD25 conjugate, e.g., an IL-2 non-blocking anti-CD25-IR700 conjugate, is administered, and the method also includes the administration of an immune checkpoint inhibitor, the double administration resulting in an enhanced effect, e.g., an additional, additive, or synergistic effect. An additional, additive, or synergistic effect refers to an effect that exceeds the effect of any single therapy alone (i.e., administration of the conjugate alone, administration of the conjugate and subsequent irradiation alone, or administration of the checkpoint inhibitor alone). For example, the administration of an IL-2 non-blocking anti-CD25-IR700 conjugate and a checkpoint inhibitor, e.g., an anti-PD-1 antibody, produces a greater effect than when the anti-CD25-IR700 conjugate alone or the checkpoint inhibitor alone is administered, or when the anti-CD25-IR700 conjugate and subsequent irradiation alone are administered. In some aspects, the methods and uses provided result in additional, additive, or synergistic antitumor responses; for example, the growth of one or both of the primary tumor and secondary populations in a subject, and / or the increase in their volume, size, or mass, and the increase in the number of cells in the secondary population, is inhibited to a greater degree or extent compared to administration of the conjugate alone, the conjugate and subsequent irradiation alone, and / or the anti-PD-1 antibody alone. In some aspects of the methods or uses provided, the growth of one or both of the primary tumor, and / or the increase in their volume, size, or mass, and the increase in the volume, size, or number of cells in the secondary population in a subject, is inhibited to a greater degree compared to administration of the conjugate and subsequent irradiation alone and compared to administration of the anti-PD-1 antibody alone. In some embodiments, the inhibition includes an increase of less than 20% in tumor volume, tumor size, or tumor mass; no change in tumor volume, size, or mass (i.e., stopped tumor growth or progression); or one or more of a reduction in tumor volume, tumor size, or tumor mass, or a reduction in the number of tumor cells. In some embodiments, the inhibition involves one or more increases of less than 20% in the number of tumor cells. In some embodiments, the method produces an enhanced response, e.g., a more complete response, a more persistent response, or a longer-lasting response.
[0131] In some embodiments, the method produces an enhanced effect on a first tumor, e.g., an additional effect, additive effect, or synergistic effect, including one or more of the following: inhibition, reduction, or elimination of tumor growth; reduction of tumor volume, size, or mass; or increase in the number of subjects with complete response; and any combination thereof. In some embodiments, the method produces an enhanced effect on invasive tumor cells, e.g., an additional effect, additive effect, or synergistic effect, including one or more of the following: inhibition, reduction, or elimination of tumor cell growth; reduction of the number or volume, size, or mass of invasive tumor cells; and any combination thereof (including combinations with the effect on one or more irradiated tumors, e.g., the effect on the first tumor). In some embodiments, the method produces an enhanced effect on metastatic tumor cells, e.g., an additional effect, additive effect, or synergistic effect, including one or more of the following: inhibition, reduction, or elimination of metastatic tumor cell growth; reduction of the number or volume, size, or mass of metastatic tumor cells; and any combination thereof (including combinations with the effect on one or more irradiated tumors). In some embodiments, the synergistic effect is achieved for tumors directly exposed to irradiation (i.e., irradiation or radiation at selected wavelengths of light). In some embodiments, the enhanced effect is achieved for unirradiated tumor cells (e.g., in this case, the first tumor is irradiated), and the synergistic effect is achieved for unirradiated metastatic or invasive tumor cells (e.g., unirradiated metastatic or invasive tumor cells located distal to the irradiated tumor).
[0132] In some embodiments, the method produces a synergistic effect on increasing or boosting systemic immunity. In some embodiments, the method produces a synergistic effect on systemic immunity as described herein or known, such as any of the measures described in Section II of this specification, for example, intratumor CD8 + T lymphocyte count, CD8 + T lymphocytes and regulatory T cells (T reg) ratio, intratumor T lymphocyte exhaustion (e.g., CD3 expressing PD-1 and / or CTLA4 markers) + CD8 + (percentage of cells), intratumor-activated CD8 + The number or percentage of T lymphocytes (e.g., CD45) + Ki67 in relation to cells + or CD69 + (Percentage of CD8 cells), expansion of cytotoxic intratumor T lymphocytes based on cytotoxicity of splenocytes against tumor cells (e.g., CD3 cells that do not express PD-1 and / or CTLA4 markers) + CD8 + It produces a synergistic effect on the proportion of cells, or any combination or all of them. In some aspects, intratumoral CD8 + T lymphocytes are CD3 + CD8 + Including cells, tumor-exhausted T lymphocytes are PD-1 + CTLA-4 + CD3 + CD8 + The activated tumor-derived CD8+ T lymphocytes, including cells, are CD3 + CD8 + Ki67 + and / or CD3 + CD8 + CD69 + The expansion of cytotoxic T lymphocytes, including PD-1 cells, is due to PD-1 - CTLA-4 - CD3 + CD8 + Contains cells.
[0133] In some embodiments, the method includes the administration of an IL-2 non-blocking anti-CD25-IR700 conjugate and an immune checkpoint inhibitor to achieve a synergistic effect. In some embodiments, the method includes the administration of an IL-2 non-blocking anti-CD25-IR700 conjugate and an anti-PD-1 antibody to achieve an enhanced effect, e.g., a synergistic or additive effect. In some embodiments, the anti-CD25-IR700 conjugate comprises basiliximab having a functional Fc region, the immune checkpoint inhibitor is an anti-PD-1 antibody such as nivolumab, and the enhanced effect, e.g., an additional, additive or synergistic effect, is found as a reduction in tumor growth, tumor volume, tumor size, tumor mass, or complete response in the irradiated tumor, and / or a reduction in the growth, number, volume, size, or mass of non-irradiated tumor cells in a secondary population of tumor cells (e.g., invasive or metastatic tumor cells). In some embodiments, administration and irradiation with an IL-2 non-blocking anti-CD25-IR700 conjugate results in a reduction in the number of intratumor Tregs and / or an increase in the intratumor CD8+ to Treg ratio or the intratumor CD4+ to Treg ratio. In some embodiments, concomitant treatment with an anti-PD-1 antibody can produce a synergistic effect with respect to a reduction in the number of intratumor Tregs and / or an increase in the intratumor CD8+ to Treg ratio or the intratumor CD4+ to Treg ratio.
[0134] V. Additional therapeutic agents In some cases, the methods and uses provided involve the administration of additional therapeutic agents or anti-cancer treatments. In some cases, the additional therapeutic agent is an immunomodulator. In some cases, the additional therapeutic agent is an anti-cancer treatment.
[0135] In some aspects, immunomodulators are cytokines. In some aspects, immunomodulators are cytokines or agents that induce increased expression of cytokines in the tumor microenvironment. In some contexts, "cytokines" refers to a general term for proteins released by a population of cells that act as intercellular mediators to other cells. Examples of such cytokines include lymphokines, monokines, and traditional polypeptide hormones. In particular, growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); hepatocyte growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-alpha and-beta; Müllerian duct inhibitor; mouse gonadotropin-related peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF-beta; platelet growth factor; transforming growth factors such as TGF-alpha and TGF-beta. Cytokines include TNF-α (TNF-α); insulin-like growth factor-I and -II; erythropoietin (EPO); bone induction factor; interferons such as interferon-alpha, beta, and gamma; colony-stimulating factors (CSFs), e.g., macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs), e.g., IL-1, IL-1-alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15; tumor necrosis factor, e.g., TNF-alpha or TNF-beta; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins of natural origin or from recombinant cell cultures, and bioactive equivalents of cytokines in their natural sequences.For example, immunomodulators are cytokines, and cytokines include IL-4, TNF-α, GM-CSF, or IL-2.
[0136] In some embodiments, the immunomodulator is selected from GM-CSF, CpG-ODN (CpG oligodeoxynucleotide), lipopolysaccharide (LPS), monophosphoryl lipid A (MPL), alum, recombinant Leishmania polyprotein, imiquimod, MF59, poly I:C, poly A:U, type 1 IFN, Pam3Cys, Pam2Cys, complete Freund's adjuvant (CFA), alpha-galactosylceramide, RC-529, MDF2P, loxolibine, anti-CD40 agonist, SIRPa antagonist, AS04, AS03, flagellin, reximod, DAP (diaminopimelic acid), MDP (muramyl dipeptide), and CAF01 (cationic adjuvant preparation-01). In some embodiments, the immunomodulator is a Toll-like receptor (TLR) agonist, adjuvant, or cytokine. In some embodiments, the immunomodulator is a TLR agonist, and the TLR agonist is a TLR4 agonist, a TLR7 agonist, a TLR8 agonist, or a TLR9 agonist. In some embodiments, the TLR agonist is selected from triacylated lipoproteins, diacylated lipopeptides, lipoteichoic acid, peptidoglycan, zymosan, Pam3CSK4, dsRNA, poly(I:C), polyG10, polyG3, CpG, 3M003, flagellin, lipopolysaccharide (LPS), Leishmania homolog of eukaryotic ribosome elongation and initiation factor 4a (LeIF), MED 19197, SD-101, and imidazoquinoline TLR agonists.
[0137] In some embodiments, the immunomodulator may contain one or more interleukins or other cytokines. For example, the interleukins may include leukocyte interleukin injections (Multikine), which are combinations of natural cytokines.
[0138] In some embodiments, the immunomodulator is a Toll-like receptor (TLR) agonist. In some embodiments, such agonists may include TLR4 agonists, TLR8 agonists, or TLR9 agonists. Such agonists may be selected from peptidoglycans, poly(I:C), CpG, 3M003, flagellin, and the Leishmania homolog (LeIF) of eukaryotic ribosome elongation and initiation factor 4a.
[0139] In some embodiments, the immunomodulators may be those that enhance the immunogenicity of tumor cells, such as patupilone (epothilone B), epidermal growth factor receptor (EGFR) targeting monoclonal antibody 7A7.27, histone deacetylase inhibitors (e.g., vorinostat, romidepsin, panobinostat, belinostat, and entinostat), n3-polyunsaturated fatty acid docosahexaenoic acid, proteasome inhibitors (e.g., bortezomib), shikonin (the main component of the root of Lithospermum erythrorhizon), and oncolytic viruses, such as TVec (tarimodine laherparepbec). In some embodiments, immunomodulatory agents such as anthracyclines (e.g., doxorubicin, mitoxantrone), BK channel agonists, bortezomib, bortezomib + mitomycin C + hTert-Ad, cardiac glycosides + non-ICD inducers, cyclophosphamide, GADD34 / PP1 inhibitors + mitomycin, LV-tSMAC, and oxaliplatin activate immunogenic cell death in cancer or tumors. In some embodiments, the immunomodulatory agent may be an epigenetic therapy, such as a DNA methyltransferase inhibitor (e.g., decitabine, 5-aza-2'-deoxycytidine).
[0140] For example, in some embodiments, immunomodulators can be DNA methyltransferase inhibitors, which can modulate the expression of tumor-associated antigens (TAAs). TAAs are antigenic substances produced in tumor cells that trigger an immune response. TAAs are often downregulated by DNA methylation in tumors, thus evading the immune system. Reversing DNA methylation restores TAA expression and increases the immunogenicity of tumor cells. For example, demethylating agents such as decitabine (5-aza-2'-deoxycytidine) can upregulate TAA expression in tumor cells and increase immune recognition of cancer cells. Photoimmunotherapy would further expose TAAs to the immune system by destroying cells.
[0141] In some embodiments, the additional therapeutic agent is an active substance or compound used in anticancer treatment, such as an anticancer agent. These include any active substances that can alleviate, reduce, improve, suppress, or induce or maintain a state of response to clinical symptoms or diagnostic markers associated with tumors and cancer, and that can be used in combinations and compositions provided herein. In some embodiments, the anticancer agent is one whose therapeutic effect is generally related to the penetration or delivery of the anticancer agent into the tumor microenvironment or tumor space. In some embodiments, the anticancer agent is an alkylating agent, a platinum compound, antimetabolites, an antitumor antibiotic, a topoisomerase inhibitor, a mitotic inhibitor, a corticosteroid, a proteasome inhibitor, a kinase inhibitor, a histone deacetylase inhibitor, or an antibody or an antigen-binding antibody fragment thereof. In some embodiments, the anticancer agent is a peptide, a protein, or a small molecule drug.
[0142] In some embodiments, anticancer drugs include 5-fluorouracil / leucovorin, oxaliplatin, irinotecan, regorafenib, ziv-aflibercept, capecitabine, cisplatin, paclitaxel, topotecan, carboplatin, gemcitabine, docetaxel, 5-FU, ifosfamide, mitomycin, pemetrexed, vinorelbine, and carmustine wafers. (Werver), temozolomide, methotrexate, capecitabine, lapatinib, etoposide, dabrafenib, vemurafenib, liposomal cytarabine, cytarabine, interferon alpha, erlotinib, vincristine, cyclophosphamide, lomustine, procarbazine, sunitinib, somatostatin, doxorubicin, pegylated liposome-encapsulated doxorubicin, epirubicin, eribulin, albumin-conjugated paclitaxel, isabepyrone, cotrimoxazole, taxane, vinblastine, temsirolimus, temozolomide, bendamustine These include oral etoposide, everolimus, octreotide, lanreotide, dacarbazine, mesna, pazopanib, eribulin, imatinib, regorafenib, sorafenib, nilotinib, dasantinib, celecoxib, tamoxifen, toremifene, dactinomycin, sirolimus, crizotinib, cerutinib, enzalutamide, abiraterone acetate, mitoxantrone, cabazitaxel, fluoropyrimidine, oxaliplatin, leucovorin, afatinib, ceritinib, gefitinib, cabozantinib, oxaliplatin, or aurorapyrimidine.
[0143] In some embodiments, anticancer agents are alkylating agents. Alkylating agents are compounds that directly damage DNA by forming covalent bonds with nucleic acids and inhibiting DNA synthesis. Exemplary alkylating agents include, but are not limited to, mechloretamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, busulfan, and thiotepa, as well as nitrosourea alkylating agents such as carmustine and lomustine.
[0144] In some embodiments, the anticancer agent is an antibody or an antigen-binding antibody fragment.
[0145] In some embodiments, the anticancer drug is a platinum-based drug. Platinum-based drugs bind to DNA, causing DNA crosslinking, which ultimately triggers apoptosis. Exemplary platinum-based drugs include, but are not limited to, cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin, and lipoplatin.
[0146] In some embodiments, anticancer agents are antimetabolites. Antimetabolites interfere with the growth of DNA and RNA by replacing the normal components of RNA and DNA. These agents damage cells during the S phase, when the cell's chromosomes are being copied. In some cases, antimetabolites can be used to treat leukemia, breast, ovarian, and intestinal cancers, as well as other types of cancer. Exemplary antimetabolites include, but are not limited to, 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), capecitabine (Xeloda®), cytarabine (Ara-C®), phloxuridine, fludarabine, gemcitabine (Gemzar®), hydroxyurea, methotrexate, and pemetrexed (Alimta®).
[0147] In some embodiments, anticancer drugs are antitumor antibiotics. Antitumor antibiotics act by altering the DNA within cancer cells, preventing them from growing and multiplying. Anthracyclines are antitumor antibiotics that interfere with enzymes involved in DNA replication. These drugs generally act at all stages of the cell cycle. They can be widely used against a wide variety of cancers. Exemplary anthracyclines include, but are not limited to, daunorubicin, doxorubicin, epirubicin, and idarubicin. Other antitumor antibiotics include actinomycin-D, bleomycin, mitomycin-C, and mitoxantrone.
[0148] In some embodiments, anticancer drugs are topoisomerase inhibitors. These drugs interfere with an enzyme called topoisomerase (which helps separate DNA strands, allowing the strands to be copied during the S phase). Topoisomerase inhibitors can be used to treat certain leukemias, as well as lung cancer, ovarian cancer, gastrointestinal cancers, and other cancers. Exemplary topoisomerase inhibitors include, but are not limited to, doxorubicin, topotecan, irinotecan (CPT-11), etoposide (VP-16), teniposide, and mitoxantrone.
[0149] In some embodiments, anticancer drugs are mitotic inhibitors. Mitotic inhibitors are often plant alkaloids and other compounds derived from natural plant products. They act by halting mitosis in the M phase of the cell cycle, but in some cases they can damage cells at all stages by preventing enzymes from producing proteins necessary for cell regeneration. Exemplary mitotic inhibitors include, but are not limited to, paclitaxel (Taxol®), docetaxel (Taxotere®), ixabepyrone (Ixempra®), vinblastine (Velban®), vincristine (Oncovin®), vinorelbine (Navelbine®), and estramustine (Emcyt®).
[0150] In some embodiments, anticancer drugs are corticosteroids. Corticosteroids, often simply called steroids, are natural hormones and hormone-like drugs useful in treating many types of cancer. Corticosteroids can also be used before chemotherapy to help prevent allergic reactions, and during and after chemotherapy to help prevent nausea and vomiting. Exemplary corticosteroids include, but are not limited to, prednisone, methylprednisolone (Solumedrol®), and dexamethasone (Decadron®).
[0151] In some embodiments, the anticancer agent is another type of chemotherapeutic agent, such as a proteasome inhibitor, kinase inhibitor, or histone deacetylase inhibitor. In other embodiments, the anticancer agent is a biologic, such as an antibody, used in cancer treatment.
[0152] VI. Irradiation and devices for use with the Method and Composition In some aspects, devices usable with the provided embodiments include optical diffusion devices that provide irradiation (or radiation, in some cases) at wavelengths (or multiple wavelengths) suitable for use with dye conjugate compositions such as phthalocyanine dye conjugates (e.g., IL-2 non-blocking anti-CD25-IR700 conjugates, such as those described herein). The irradiation device may include a light source (e.g., a laser) and means for delivering light to an area of interest (e.g., one or more fibers for irradiating an isolated area or isolated lesion or tumor of the object). Exemplary irradiation devices are described in U.S. Patents 10,295,719; 10,527,771; and 10,416,366, which are incorporated herein by reference. Such devices deliver light to a target area of the object using an optical diffusion device containing a non-circular core optical fiber functionally connected to a laser. In some embodiments, the core optical fiber is circular and is wound or bent before interfaced with the optical diffusion device. In certain scenarios, the device delivers a "top-hat" core irradiance distribution to deliver uniform light to the irradiated area. The light diffusion device can be a cylindrical diffuser for use, for example, for intratumor or intratissue radiation. In some embodiments, the light diffusion device is a frontal diffuser with a lens, where the irradiation is projected through the lens of the frontal diffuser at the end of the optical fiber. The projected light can be a parallel or dispersed light beam.
[0153] In some embodiments, the target region, e.g., tumor, tumor vicinity, lymph node, lymph node vicinity, is defined as ranging from 400 nm or about 400 nm to 900 nm or about 900 nm, e.g., from 500 nm or about 500 nm to 900 nm or about 900 nm, e.g., from 600 nm or about 600 nm to 850 nm or about 850 nm, e.g., from 600 nm or about 600 nm to 740 nm or about 740 nm, e.g., from 660 nm or about 660 nm to 740 nm or about 740 nm, e.g., from 660 nm or about 660 nm to 710 nm or about 710 nm, 660 nm Light with wavelengths within the range of m or approximately 660nm to 700nm or approximately 700nm, 660 or approximately 660 to 685 or approximately 685, 665 or approximately 665 to 680 or approximately 680, 670 or approximately 670 to 685 or approximately 685, 670nm or approximately 670nm to 690nm or approximately 690nm, 670 or approximately 670 to 680 or approximately 680, 680nm or approximately 680nm to 740nm or approximately 740nm, or 690nm or approximately 690nm to 710nm or approximately 710nm is irradiated. In some embodiments, a target area, such as a tumor, tumor periphery, lymph node, lymph node periphery, or tumor microenvironment, is irradiated with light of wavelengths from 600 nm or about 600 nm to 850 nm or about 850 nm, for example, from 660 nm or about 660 nm to 740 nm or about 740 nm. In some embodiments, a target area, such as a tumor, tumor vicinity, lymph node, lymph node vicinity, or tumor microenvironment, is irradiated with light of wavelengths of at least 600 nm, 620 nm, 640 nm, 660 nm, 680 nm, 700 nm, 720 nm, or 740 nm, or at least about 600 nm, 620 nm, 640 nm, 660 nm, 680 nm, 700 nm, 720 nm, or 740 nm, for example 690 ± 50 nm or about 690 ± 50 nm, or 690 ± 40 nm or about 690 ± 40 nm, for example 690 nm or about 690 nm, or 680 nm or about 680 nm.In some embodiments, the target area, e.g., tumor, tumor vicinity, lymph node, lymph node vicinity, or tumor microenvironment, is irradiated with light of a wavelength of 670 ± 50 nm or approximately 670 ± 50 nm, or 670 ± 40 nm or approximately 670 ± 40 nm, for example, 670 nm or approximately 670 nm. In some embodiments, the target area, e.g., tumor, tumor vicinity, lymph node, lymph node vicinity, or tumor microenvironment, is irradiated with light of a wavelength of less than 685 nm or 680 nm, or approximately 685 nm or less than 680 nm.
[0154] In some of the arbitrary embodiments, the wavelength of light used for irradiation depends on the phthalocyanine dye. For example, if the Si-phthalocyanine dye is IR700, irradiation can be carried out at a wavelength of 690 nm ± 20 nm. In some cases, the Si-phthalocyanine dye is of formula (I) If TIFF0007948938000021.tif69128, or its salts, stereoisomers, or tautomers, is irradiated at a wavelength of 660 nm ± 50 nm.
[0155] In some embodiments of the methods and uses provided herein, interstitial irradiation is performed using cylindrical diffusion fibers with a diffuser length ranging from 0.5 cm or about 0.5 cm to 10 cm or about 10 cm and positioned at a distance of 1.8 ± 0.2 cm or about 1.8 ± 0.2 cm. In some embodiments, the light (irradiation) dose ranges from 2 J / fiber length cm or about 2 J / fiber length cm to 500 J / fiber length cm or about 500 J / fiber length cm. In some embodiments, the interstitial light (irradiation) dose ranges from 20 J / fiber length cm or about 20 J / fiber length cm to 500 J / fiber length cm or about 500 J / fiber length cm. In some embodiments, the optical power (or optical fluence) of the interstitial light dose ranges from 100 mW / fiber length cm or about 100 mW / fiber length cm to 500 mW / fiber length cm or about 500 mW / fiber length cm. In some embodiments, light is supplied for a period ranging from 120 seconds or about 120 seconds to 600 seconds or about 600 seconds. In some embodiments, light is given for at least 100 seconds, 120 seconds, 150 seconds, 180 seconds, 200 seconds, 220 seconds, 250 seconds, 270 seconds, 300 seconds, 310 seconds, 330 seconds, 340 seconds, 350 seconds, 370 seconds, 380 seconds, 400 seconds, 420 seconds, 440 seconds, 460 seconds, 480 seconds, or 500 seconds, or at least about 100 seconds, 120 seconds, 150 seconds, 180 seconds, 200 seconds, 220 seconds, 250 seconds, 270 seconds, 300 seconds, 310 seconds, 330 seconds, 340 seconds, 350 seconds, 370 seconds, 380 seconds, 400 seconds, 420 seconds, 440 seconds, 460 seconds, 480 seconds, or 500 seconds. In some cases, the tumor is 10 mm or deeper than approximately 10 mm, or it is a subcutaneous tumor.
[0156] In some embodiments, the method provided includes interstitial irradiation of a target region, which is a tumor such as a stromal tumor in the subject, for 250 seconds or about 250 seconds, with a light dose of 100 J / fiber length cm or about 100 J / fiber length cm, and a light fluence of 400 mW / cm or about 400 mW / cm, using a cylindrical diffusion fiber having a diffuser length of 0.5 cm or about 0.5 cm to 10 cm or about 10 cm and positioned at a distance of 1.8 ± 0.2 cm or about 1.8 ± 0.2 cm. In some embodiments, the target region is a tumor that is greater than 10 mm or about 10 mm in depth or is a subcutaneous tumor. In some embodiments, the cylindrical diffusion fiber is placed in a catheter positioned at a distance of 1.8 ± 0.2 cm or about 1.8 ± 0.2 cm within the tumor. In some embodiments, the catheter is optically transparent.
[0157] In some embodiments, the target region, e.g., tumor, tumor vicinity, lymph node, lymph node vicinity, or tumor microenvironment, is at least 1 J / cm². 2 Or at least about 1 J / cm² 2 For example, at least 10 J / cm² 2 Or at least about 10 J / cm² 2 at least 30 J / cm² 2 Or at least about 30 J / cm² 2 at least 50 J / cm² 2 Or at least about 50 J / cm² 2 at least 100 J / cm² 2 Or at least about 100 J / cm² 2 , or at least 500 J / cm² 2 Or at least about 500 J / cm² 2 A dose of light, for example, a superficial dose, is irradiated. In some embodiments, the irradiation dose is 1 or about 1, J / cm². 2 Or approximately J / cm 2 Up to 1 or approximately 1, 500 J / cm² 2 Alternatively, approximately 500 J / cm² 2 Up to 5 or approximately 5, 200 J / cm² 2 Alternatively, approximately 200 J / cm² 2Up to 10 or approximately 10 to 100 J / cm² 2 Alternatively, approximately 100 J / cm² 2 Up to 10 or approximately 10 to 50 J / cm² 2 Alternatively, approximately 50 J / cm² 2 Up to, or 25 or approximately 25, 400 J / cm² 2 Alternatively, approximately 400 J / cm² 2 Up to. In some embodiments, the target area is at least 2 J / cm 2 , 5J / cm 2 , 10J / cm 2 , 25J / cm 2 , 30 J / cm 2 50 J / cm 2 75 J / cm 2 , 100 J / cm 2 , 150 J / cm 2 , 200 J / cm 2 300 J / cm² 2 400 J / cm² 2 , or 500 J / cm² 2 , or at least about 2J / cm 2 , 5J / cm 2 , 10J / cm 2 , 25J / cm 2 30 J / cm 2 50 J / cm 2 75 J / cm 2 , 100 J / cm 2 , 150 J / cm 2 , 200 J / cm 2 300 J / cm² 2 , 400 J / cm 2 , or 500 J / cm² 2 The radiation dose is irradiated at this dose. In some embodiments, the light (irradiation) dose is 25 J / cm². 2 Or approximately 25 J / cm 2 From 400 J / cm² 2 Or approximately 400 J / cm² 2 Up to 50 mW / cm². In some embodiments, the optical power (or optical fluence) of the light dose is 50 mW / cm². 2 Or approximately 50 mW / cm² 2 From 200mW / cm 2 Or approximately 200 mW / cm² 2Up to, for example, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 mW / cm². 2 , or approximately 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 mW / cm² 2 This is the optical power. In some embodiments, the light is supplied for a period ranging from 120 seconds or about 120 seconds to 600 seconds or about 600 seconds. In some embodiments, light is given for at least 100 seconds, 120 seconds, 150 seconds, 180 seconds, 200 seconds, 220 seconds, 250 seconds, 270 seconds, 300 seconds, 310 seconds, 330 seconds, 340 seconds, 350 seconds, 370 seconds, 380 seconds, 400 seconds, 420 seconds, 440 seconds, 460 seconds, 480 seconds, or 500 seconds, or at least about 100 seconds, 120 seconds, 150 seconds, 180 seconds, 200 seconds, 220 seconds, 250 seconds, 270 seconds, 300 seconds, 310 seconds, 330 seconds, 340 seconds, 350 seconds, 370 seconds, 380 seconds, 400 seconds, 420 seconds, 440 seconds, 460 seconds, 480 seconds, or 500 seconds.
[0158] In some embodiments, the target area is a tumor, which is a superficial tumor. In some embodiments, the tumor is less than 10 mm thick. In some embodiments, irradiation is performed using a fiber optic cable with a microlens at its tip for surface or superficial irradiation. In some embodiments, the light dose is 5 J / cm². 2 Or approximately 5J / cm 2 From 200 J / cm² 2 Or approximately 200 J / cm² 2 Up to this point. In some embodiments, the light irradiation dose is 25 J / cm². 2 Or approximately 25 J / cm 2 From 400 J / cm² 2 Or approximately 400 J / cm² 2 Up to this point. In some embodiments, the optical power of the light dose is 50 mW / cm². 2 Or approximately 50 mW / cm² 2 From 200mW / cm 2 Or approximately 200 mW / cm² 2Up to [a certain point]. In some embodiments, the light irradiation dose is 50 J / cm². 2 Or approximately 50 J / cm² 2 And, 150 mW / cm 2 Or approximately 150 mW / cm² 2 With that optical power, it lasts for 333 seconds or approximately 333 seconds.
[0159] In some embodiments, a target area, such as a tumor, tumor vicinity, lymph node, lymph node vicinity, or tumor microenvironment, is irradiated with a dose of at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length, for example, at least 10 J / cm of fiber length or at least about 10 J / cm of fiber length, at least 50 J / cm of fiber length or at least about 50 J / cm of fiber length, at least 100 J / cm of fiber length or at least about 100 J / cm of fiber length, at least 250 J / cm of fiber length or at least about 250 J / cm of fiber length, or at least 500 J / cm of fiber length or at least about 500 J / cm of fiber length. In some embodiments, the irradiation dose is 1 or about 1 to 1000 J / fiber length cm or about 1000 J / fiber length cm, 1 or about 1 to 500 J / fiber length cm or about 500 J / fiber length cm, 2 or about 2 to 500 J / fiber length cm or about 500 J / fiber length cm, 50 or about 50 to 300 J / fiber length cm or about 300 J / fiber length cm, 10 or about 10 to 100 J / fiber length cm or about 100 J / fiber length cm, or 10 or about 10 to 50 J / fiber length cm or about 50 J / fiber length cm. In some embodiments, the target region, e.g., tumor, tumor vicinity, lymph node, lymph node vicinity, or tumor microenvironment, is subjected to at least 2 J / cm of fiber length, 5 J / cm of fiber length, 10 J / cm of fiber length, 25 J / cm of fiber length, 50 J / cm of fiber length, 75 J / cm of fiber length, 100 J / cm of fiber length, 150 J / cm of fiber length, 200 J / cm of fiber length, 250 J / cm of fiber length, 300 J / cm of fiber length, and 400 J / cm of fiber length. The radiation dose is 500 J / cm of fiber length, or at least approximately 2 J / cm of fiber length, 5 J / cm of fiber length, 10 J / cm of fiber length, 25 J / cm of fiber length, 50 J / cm of fiber length, 75 J / cm of fiber length, 100 J / cm of fiber length, 150 J / cm of fiber length, 200 J / cm of fiber length, 250 J / cm of fiber length, 300 J / cm of fiber length, 400 J / cm of fiber length, or 500 J / cm of fiber length.In some embodiments, irradiation is performed for 250 seconds or approximately 250 seconds at a dose of 100 J / cm or about 100 J / cm and a fluence rate of 400 mW / cm or about 400 mW / cm.
[0160] In some embodiments, the provided method uses a fiber with a microlens at its tip for surface irradiation, at 5 J / cm 2 Or approximately 5J / cm 2 From 200 J / cm² 2 Or approximately 200 J / cm² 2 The process includes irradiating a target area, which is a superficial tumor, with a light dose up to 25 J / cm². In some embodiments, the light irradiation dose is 25 J / cm². 2 Or approximately 25 J / cm 2 From 400 J / cm² 2 Or approximately 400 J / cm² 2 Up to [a certain point]. In some embodiments, the light irradiation dose is 50 J / cm². 2 Or approximately 50 J / cm² 2 In some cases, irradiation of superficial tumors is 50 J / cm². 2 Or approximately 50 J / cm² 2 At this dose, 150 mW / cm² 2 Or approximately 150 mW / cm² 2 It will be administered for 333 seconds or approximately 333 seconds at that fluence rate.
[0161] In some cases, the radiation dose required to achieve PIT in humans may be lower than the radiation dose required for PIT in mice. For example, in some cases, 50 J / cm² in an in vivo tumor mouse model. 2 Or approximately 50 J / cm² 2 (50J / cm 2 The photodose method is not effective for PIT, which is in contrast to what can be observed in clinical practice in human patients.
[0162] In some embodiments, the irradiation dose after administration of a composition containing a phthalocyanine dye-targeting molecule conjugate is at least 1 J / cm² at a wavelength of 660–740 nm or approximately 660–740 nm.2 Or at least about 1 J / cm² 2 Alternatively, at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length, for example, at wavelengths of 660-740 nm or at least 10 J / cm 2 Or at least about 10 J / cm² 2 Alternatively, at least 10 J / cm of fiber length or at least about 10 J / cm of fiber length, at wavelengths of 660-740 nm or about 660-740 nm, at least 50 J / cm 2 Or at least about 50 J / cm² 2 Alternatively, at least 50 J / cm of fiber length or at least about 50 J / cm of fiber length, or at least 100 J / cm at wavelengths of 660-740 nm or about 660-740 nm. 2 Or at least about 100 J / cm² 2 Alternatively, it is at least 100 J / cm of fiber length or at least about 100 J / cm of fiber length. In some embodiments, the wavelength is 660-710 nm. In some embodiments, the irradiation dose after administration of the composition containing the phthalocyanine dye-targeting molecule conjugate is at least 1.0 J / cm at a wavelength of 690 nm or about 690 nm. 2 Or at least about 1.0 J / cm² 2 Alternatively, at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length, for example, at a wavelength of 690 nm or about 690 nm, at least 10 J / cm 2 Or at least about 10 J / cm² 2 Alternatively, at least 10 J / cm of fiber length or at least about 10 J / cm of fiber length, at a wavelength of 690 nm or about 690 nm, at least 50 J / cm 2 Or at least about 50 J / cm² 2 Alternatively, at least 50 J / cm of fiber length or at least about 50 J / cm of fiber length, or at least 100 J / cm at a wavelength of 690 nm or about 690 nm. 2 Or at least about 100 J / cm² 2Alternatively, at least 100 J / cm of fiber length or at least about 100 J / cm of fiber length, for example, at a wavelength of 690 nm or about 690 nm, 1.0 to 500 J / cm 2 Or 1.0 to 500 J / cm of fiber length. Exemplary irradiation after administration of the conjugate or composition provided herein is at least 1 J / cm at wavelengths from 660 nm or about 660 nm to 740 nm or about 740 nm. 2 Or at least about 1 J / cm² 2 Alternatively, the process may include irradiating a target area with a dose of at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length.
[0163] In some embodiments, the irradiation dose after administration of a composition containing a phthalocyanine dye-targeting molecule conjugate is at least 1 J / cm² at a wavelength of 600-800 nm or approximately 600-800 nm. 2 Or at least about 1 J / cm² 2 Alternatively, at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length, for example, at wavelengths of 620-720 nm or about 620-720 nm, at least 1 J / cm 2 Or at least about 1 J / cm² 2 Alternatively, at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length, at wavelengths of 620-720 nm or about 620-720 nm, at least 10 J / cm 2 Or at least about 10 J / cm² 2 Alternatively, at least 10 J / cm of fiber length or at least about 10 J / cm of fiber length, at wavelengths of 620-720 nm or about 620-720 nm, at least 50 J / cm 2 Or at least about 50 J / cm² 2 Alternatively, at least 50 J / cm of fiber length or at least about 50 J / cm of fiber length, or at least 100 J / cm at wavelengths of 620-720 nm or about 620-720 nm. 2 Or at least about 100 J / cm² 2Alternatively, it is at least 100 J / cm of fiber length or at least about 100 J / cm of fiber length. In some embodiments, the wavelength is 640-700 nm. In some embodiments, the irradiation dose after administration of the composition containing the phthalocyanine dye-targeting molecule conjugate is at least 1.0 J / cm at a wavelength of 670 nm or about 670 nm. 2 Or at least about 1.0 J / cm² 2 Alternatively, at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length, for example, at a wavelength of 670 nm or about 670 nm, at least 10 J / cm 2 Or at least about 10 J / cm² 2 Alternatively, at least 10 J / cm of fiber length or at least about 10 J / cm of fiber length, at a wavelength of 670 nm or about 670 nm, at least 50 J / cm 2 Or at least about 50 J / cm² 2 Alternatively, at least 50 J / cm of fiber length or at least about 50 J / cm of fiber length, or at least 100 J / cm at a wavelength of 670 nm or about 670 nm. 2 Or at least about 100 J / cm² 2 Alternatively, at least 100 J / cm of fiber length or at least about 100 J / cm of fiber length, for example, at a wavelength of 670 nm or about 670 nm, 1.0 to 500 J / cm 2 Or 1.0 to 500 J / cm of fiber length. An exemplary irradiation after administration of the conjugate or composition provided herein is at least 1 J / cm at wavelengths from 620 nm or about 620 nm to 720 nm or about 720 nm. 2 Or at least about 1 J / cm² 2 Alternatively, the process may include irradiating a target area with a dose of at least 1 J / cm of fiber length or at least about 1 J / cm of fiber length.
[0164] In some embodiments, the irradiation step involves irradiating at wavelengths from 600 nm or approximately 600 nm to 850 nm or approximately 850 nm at a rate of 25 J / cm². 2 Alternatively, approximately 25 J / cm² 2 From 400 J / cm² 2Alternatively, approximately 400 J / cm² 2 The dose is up to or from 2 J / fiber length cm or approximately 2 J / fiber length cm to 500 J / fiber length cm or approximately 500 J / fiber length cm. In some embodiments, the target area is irradiated at a wavelength of 690 ± 40 nm. In some embodiments, the target area is irradiated at 50 J / cm 2 Alternatively, approximately 50 J / cm² 2 Alternatively, the radiation dose is 100 J / cm of fiber length or approximately 100 J / cm of fiber length.
[0165] In some embodiments, light or lasers may be applied to pigment molecules, for example, cells containing conjugates, for a period ranging from 5 seconds or about 5 seconds to 5 minutes or about 5 minutes. For example, in some embodiments, light or lasers may be applied to activate pigment molecules for 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or 55 seconds, or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or 55 seconds, or within a range between any two such values. In some embodiments, light or lasers may be applied for 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 minutes, or about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 minutes, or longer, or within a range between any two such values. In some embodiments, the length of time for which light or lasers are applied may vary depending on the energy, for example, the wattage of the light or laser. For example, light or lasers with lower wattage can be applied for a longer period of time to activate the pigment molecules.
[0166] In some embodiments, light or laser may be applied from 30 minutes or about 30 minutes to 96 hours or about 96 hours after administration of the conjugate. For example, in some embodiments, light or laser may be applied at 30, 35, 40, 45, 50 or 55 minutes, or about 30, 35, 40, 45, 50 or 55 minutes, or within a range between any two such values. In some embodiments, light or laser is applied 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 hours after administering the conjugate, or approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 hours, or within a range between approximately any two such values, for example, between 20 hours or approximately 20 hours and 28 hours or approximately 28 hours, or approximately 24 hours ± 4 hours. In some embodiments, light or laser may be applied between 1 and 24 hours or approximately 1 and 24 hours after administration of the conjugate, for example between 1 or approximately 1 and 12 hours or approximately 12 hours, between 12 or approximately 12 hours or approximately 24 hours, between 6 or approximately 6 and 12 hours or approximately 12 hours, or more than 24 hours or more than approximately 24 hours. In some embodiments, light or laser may be applied at 36, 48, 72 or 96 hours or approximately 36, 48, 72 or 96 hours after administration of the conjugate. In some embodiments, light or laser may be applied at 24 hours ± 4 hours or approximately 24 hours ± 4 hours after administration of the conjugate.
[0167] In some embodiments, a target area, such as a tumor, tumor vicinity, lymph node, lymph node vicinity, or tumor microenvironment, or the target itself, can be irradiated once or multiple times. Thus, irradiation can be completed in one day, or repeated over multiple days with the same or different doses, for example, at least two different times, three different times, four different times, five different times or ten different times, or at least about two different times, three different times, four different times, five different times or ten different times. In some embodiments, repeated irradiation can be performed on the same day, daily, or every 1-3 days, every 3-7 days, every 1-2 weeks, every 2-4 weeks, every 1-2 months, or at longer intervals. In some embodiments, multiple irradiations, for example, at least two, at least three, or at least four irradiations, for example, two, three, four, five, six, seven, eight, nine, or ten separate doses are performed.
[0168] In some embodiments, the dose or method of irradiation varies depending on the type or morphology of the target area, such as a tumor, tumor vicinity, lymph node, or lymph node vicinity.
[0169] In some embodiments, irradiation is performed using a device having a “top-hat” irradiance distribution profile, such as those described in WO2018 / 080952 and US20180239074.
[0170] VII. Definition Unless otherwise defined, all technical terms, notations, and other technical and scientific terms or vocabulary used herein are intended to have the same meaning as that ordinarily understood by those skilled in the art in which the claimed subject matter relates. In some cases, terms that have an ordinarily understood meaning are defined herein for clarity and / or for immediate reference, but the inclusion of such definitions herein should not necessarily be interpreted as representing a substantial difference from the generally understood meaning in the art.
[0171] As used herein, the singular forms “a,” “an,” and “the” refer to multiple objects unless otherwise clearly indicated by the context. For example, “a” or “an” means “at least one” or “one or more.” The aspects and variations described herein are understood to include “consisting of” and / or “essentially consisting of” aspects and variations.
[0172] Throughout this disclosure, various aspects of the claimed subject matter are presented in scope form. It should be understood that the scope form is merely for convenience and simplification and should not be interpreted as a definitive limitation on the scope of the claimed subject matter. Therefore, the scope description should be considered to specifically disclose all possible sub-scopes and the individual numerical values within those scopes. For example, if a range of values is provided, it should be understood that each intermediate value between the upper and lower limits of that range, and any other defined or intermediate values within that defined range, are included within the claimed subject matter. The upper and lower limits of these smaller ranges may independently be included within their smaller ranges, and these, too, are included within the claimed subject matter according to any specifically excluded limits within the defined range. If a defined range includes one or both of the limits, the range excluding one or both of those included limits is also included within the claimed subject matter. This applies regardless of the width of the range.
[0173] Where used herein, the term "approximately" refers to the normal margin of error for each value, as is obvious to those skilled in the art. References to values or parameters with "approximately" in this specification include (and describe) aspects directed toward the value or parameter itself. For example, a description referring to "approximately X" includes a description of "X".
[0174] As used herein, “conjugate” refers to a targeting molecule directly or indirectly linked to a photoactivatable dye, such as those produced by chemical conjugates or by any other method. For example, a conjugate may refer to a phthalocyanine dye (such as an IR700 molecule) directly or indirectly linked to one or more targeting molecules (such as polypeptides that bind to or target cell surface proteins). The targeting molecules may be polypeptides, more than one polypeptide, antibodies, or chemical moieties.
[0175] As used herein, "IL-2 non-blocking anti-CD25 conjugate" refers to a conjugate having a targeting molecule that binds to CD25 but does not substantially or significantly block the binding of IL-2 to CD25 and / or substantially or significantly block or interfere with IL-2 signaling. An IL-2 non-blocking anti-CD25 conjugate may have a targeting molecule, which is an antibody, antigen-binding fragment, or other part, that binds to CD25 but does not substantially or significantly block the binding of IL-2 to CD25.
[0176] A "monoclonal antibody" is an antibody produced by a single clone of a B lymphocyte or by cells transfected with the light and heavy chain genes of a single antibody. Monoclonal antibodies are produced by methods known to those skilled in the art, for example, by creating hybrid antibody-forming cells from a fusion of myeloma cells and immune splenocytes. Monoclonal antibodies include humanized monoclonal antibodies.
[0177] "Specifically binding" refers to the ability of an individual antibody to specifically trigger an immune response to an antigen, such as a tumor-specific antigen, compared to binding to unrelated proteins, such as non-tumor proteins (e.g., β-actin). For example, a CD25-specific binder binds substantially only to the CD25 protein in vitro or in vivo. As used herein, the term "tumor-specific binder" includes tumor-specific antibodies and other active agents in their preparations that bind substantially only to tumor-specific proteins.
[0178] An "antibody-IR700 molecule" or "antibody-IR700 conjugate" refers to a molecule that contains both an antibody, such as a tumor-specific antibody, conjugated to IR700. In some examples, the antibody is a humanized antibody (such as a humanized monoclonal antibody) that specifically binds to surface proteins on cancer cells.
[0179] An "antigen" refers to a compound, composition, or substance that can stimulate antibody production or a T-cell response in an animal, including compositions injected into or absorbed by an animal (such as those containing tumor-specific proteins). Antigens react with specific humoral or cellular immune products, including those induced by heterologous antigens such as the disclosed antigen. An "epitope" or "antigenic determinant" refers to a region of an antigen to which B cells and / or T cells respond. In one embodiment, T cells respond to an epitope when it is presented together with an MHC molecule. Epitopes can be formed by tertiary folding of a protein from both adjacent continuous or discontinuous amino acids. Epitopes formed from continuous amino acids are typically retained even when exposed to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost upon treatment with denaturing solvents. Epitopes typically contain at least three, more commonly at least five, about nine, or about eight to ten amino acids in their unique spatial structure. Methods for determining the spatial three-dimensional structure of an epitope include, for example, X-ray crystallography and nuclear magnetic resonance.
[0180] Examples of antigens include, but are not limited to, peptides, lipids, polysaccharides, and nucleic acids that contain antigenic determinants, such as those recognized by immune cells. In some examples, antigens include tumor-specific peptides (such as those found on the surface of cancer cells) or their immunogenic fragments.
[0181] An "immune checkpoint inhibitor" is a type of drug that blocks certain proteins produced by certain immune system cells, such as T cells, and certain cancer cells. These proteins help suppress the immune response and can prevent T cells from killing cancer cells. When these proteins are blocked, the "brakes" on the immune system are released, allowing T cells to kill cancer cells more effectively. Examples of checkpoint proteins found on T cells or cancer cells include PD-1 / PD-L1 and CTLA-4 / B7-1 / B7-2. Several immune checkpoint inhibitors are used to treat cancer.
[0182] As used herein, a combination refers to any association between two or more items. A combination can be two or more separate items, such as two compositions or two collectibles, a mixture thereof, such as a single mixture of two or more items, or a variation thereof. The components of a combination are generally functionally related or related.
[0183] As used herein, “combination therapy” refers to a treatment in which two or more therapeutic agents, for example, at least two or at least three therapeutic agents are administered to a subject to treat a single disease. In some embodiments, each therapy may produce an independent pharmaceutical effect, or together they may produce an additive or synergistic pharmaceutical effect.
[0184] As used herein, “treating” a subject with a disease or condition means that, after treatment, the symptoms of the subject are partially or completely alleviated or kept in a stable state. Thus, treatment includes prevention, therapy, and / or cure. Prevention refers to the suppression of the potential disease and / or the suppression of the worsening of the symptoms or progression of the disease.
[0185] As used herein, “treatment” means any method that improves or otherwise alters the symptoms of a condition, disorder, or disease or other indication.
[0186] As used herein, “therapeutic effect” means any effect resulting from the treatment in question that alters, typically improves, or ameliorates the symptoms of a disease or condition, or that cures the disease or condition.
[0187] As used herein, “therapeutic amount” or “therapeutic dose” means an amount of an active substance, compound, material, or composition containing the compound that is sufficient to produce at least a therapeutic effect. Thus, it is the amount necessary to suppress, cure, improve, stop, or partially stop the symptoms of a disease or disorder.
[0188] As used herein, improvement of symptoms of a particular disease or disorder by treatment, for example by administration of a pharmaceutical composition or other therapeutic agent, means any relief, whether permanent or temporary, persistent or transient, of symptoms that may be caused by or related to the administration of the composition or therapeutic agent.
[0189] As used herein, the term "subject" refers to animals, including mammals such as humans.
[0190] As used herein, “optional” or “optionally” means whether or not the event or situation described thereafter occurs, and that the description includes both the cases in which such event or situation occurs and the cases in which it does not occur. For example, “optionally substituted” means that the group is either not substituted or substituted.
[0191] All publications referenced in this application, including patent documents, scientific articles, and databases, are incorporated by reference in whole for all purposes to the same extent as each individual publication had been incorporated by reference. If any definition provided herein conflicts with, or otherwise does not match, any definition provided in a patent, patent application, published patent application, or other publication incorporated herein by reference, the definition provided herein shall prevail over the definition incorporated herein by reference.
[0192] Section headings used in this specification are for organizational purposes only and should not be construed as limiting the subjects described herein.
[0193] VIII. Exemplary Examples In particular, the embodiments provided herein are as follows: 1. A compound comprising an antibody or antigen-binding fragment that specifically binds to CD25 without substantially blocking or interfering with IL-2 signaling, and a Si-phthalocyanine dye. Irradiation at wavelengths ranging from 600 nm or approximately 600 nm to 850 nm or approximately 850 nm activates and causes cell death. Conjugate. 2. The conjugate of embodiment 1, wherein the activated conjugate does not substantially block or interfere with IL-2 signaling. 3. A conjugate according to embodiment 1 or 2, wherein the Si-phthalocyanine dye is IR700. 4. Si-phthalocyanine dyes are produced by formula (I): A conjugate according to embodiment 1 or 2, having the structure of TIFF0007948938000022.tif71128, or being a salt, stereoisomer, or tautomer thereof. 5. A conjugate according to any of embodiments 1 to 4, wherein the activated conjugate causes tumor inhibition or death at a higher level, activity, or potency than the unconjugated antibody. 6. The antibody or antigen-binding fragment is heavy chain variable (V H ) region and light chain variable (V L ) including the region, where, Applicable V H The region is V, indicated by SEQ ID NO:1. H The region contains heavy chain complementarity determination region 1 (CDR-H1), heavy chain complementarity determination region 2 (CDR-H2), and heavy chain complementarity determination region 3 (CDR-H3) contained within the amino acid sequence, and the V L The region is V, indicated by SEQ ID NO:2. L It contains light chain complementarity determination region 1 (CDR-L1), light chain complementarity determination region 2 (CDR-L2), and light chain complementarity determination region 3 (CDR-L3) within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:3. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:4. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:5. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:6. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:7.H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:8. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:9. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:11. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:9. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:12. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is indicated by SEQ ID NO:10 V H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:11. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is indicated by SEQ ID NO:10 V H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:12. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:13. HThe V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:16. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:13. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:17. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:13. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:18. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:13. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:19. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is indicated by SEQ ID NO:14 V H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:16. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is indicated by SEQ ID NO:14 V HThe V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:17. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is indicated by SEQ ID NO:14 V H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:18. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is indicated by SEQ ID NO:14 V H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:19. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:15. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:16. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:15. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:17. L Contains CDR-L1, CDR-L2, and CDR-L3 within the regional amino acid sequence; Applicable V H The region is V, indicated by SEQ ID NO:15. HThe V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:18. L Including CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence; or Applicable V H The region is V, indicated by SEQ ID NO:15. H The V contains CDR-H1, CDR-H2, and CDR-H3 contained within the regional amino acid sequence, L The region is V, indicated by SEQ ID NO:19. L Including CDR-L1, CDR-L2, and CDR-L3 contained within the regional amino acid sequence, A conjugate according to any of the following embodiments: 1 to 5. 7. The antibody or antigen-binding fragment is heavy chain variable (V H ) region and light chain variable (V L ) including the region, where, Applicable V H The region includes heavy chain complementarity determination region 1 (CDR-H1) containing the amino acid sequence shown in SEQ ID NO:20; heavy chain complementarity determination region 2 (CDR-H2) containing the amino acid sequence shown in SEQ ID NO:21; and heavy chain complementarity determination region 3 (CDR-H3) containing the amino acid sequence shown in SEQ ID NO:22. L The region includes light chain complementarity determination region 1 (CDR-L1) containing the amino acid sequence shown in SEQ ID NO:23; light chain complementarity determination region 2 (CDR-L2) containing the amino acid sequence shown in SEQ ID NO:24; and light chain complementarity determination region 3 (CDR-L3) containing the amino acid sequence shown in SEQ ID NO:25; Applicable V H The region includes CDR-H1 containing the amino acid sequence shown in SEQ ID NO:26; CDR-H2 containing the amino acid sequence shown in SEQ ID NO:27; and CDR-H3 containing the amino acid sequence shown in SEQ ID NO:28. LThe region includes CDR-L1 containing the amino acid sequence shown in SEQ ID NO:29; CDR-L2 containing the amino acid sequence shown in SEQ ID NO:24; and CDR-L3 containing the amino acid sequence shown in SEQ ID NO:30. Applicable V H The region includes CDR-H1 containing the amino acid sequence shown in SEQ ID NO:31; CDR-H2 containing the amino acid sequence shown in SEQ ID NO:32; and CDR-H3 containing the amino acid sequence shown in SEQ ID NO:33. L The region includes CDR-L1 containing the amino acid sequence shown in SEQ ID NO:34; CDR-L2 containing the amino acid sequence shown in SEQ ID NO:35; and CDR-L3 containing the amino acid sequence shown in SEQ ID NO:36; or Applicable V H The region includes CDR-H1 containing the amino acid sequence shown in SEQ ID NO:37; CDR-H2 containing the amino acid sequence shown in SEQ ID NO:38; and CDR-H3 containing the amino acid sequence shown in SEQ ID NO:39. L The region includes CDR-L1 containing the amino acid sequence shown in SEQ ID NO:40; CDR-L2 containing the amino acid sequence shown in SEQ ID NO:41; and CDR-L3 containing the amino acid sequence shown in SEQ ID NO:42. A conjugate according to any of the embodiments 1 to 6. 8. The antibody or antigen-binding fragment is heavy chain variable (V H ) region and light chain variable (V L ) including the region, where, Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:1, and the V L The region contains the amino acid sequence shown in SEQ ID NO:2; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:3, and the V L The region contains the amino acid sequence shown in SEQ ID NO:4; Applicable V HThe region includes the amino acid sequence shown in SEQ ID NO:5, and the V L The region contains the amino acid sequence shown in SEQ ID NO:6; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:7, and the V L The region contains the amino acid sequence shown in SEQ ID NO:8; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:9, and the V L The region contains the amino acid sequence shown in SEQ ID NO:11; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:9, and the V L The region contains the amino acid sequence shown in SEQ ID NO:12; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:10, and the V L The region contains the amino acid sequence shown in SEQ ID NO:11; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:10, and the V L The region contains the amino acid sequence shown in SEQ ID NO:12; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:13, and the V L The region contains the amino acid sequence shown in SEQ ID NO:16; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:13, and the V L The region contains the amino acid sequence shown in SEQ ID NO:17; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:13, and the V L The region contains the amino acid sequence shown in SEQ ID NO:18; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:13, and the V LThe region contains the amino acid sequence shown in SEQ ID NO:19; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:14, and the V L The region contains the amino acid sequence shown in SEQ ID NO:16; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:14, and the V L The region contains the amino acid sequence shown in SEQ ID NO:17; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:14, and the V L The region contains the amino acid sequence shown in SEQ ID NO:18; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:14, and the V L The region contains the amino acid sequence shown in SEQ ID NO:19; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:15, and the V L The region contains the amino acid sequence shown in SEQ ID NO:16; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:15, and the V L The region contains the amino acid sequence shown in SEQ ID NO:17; Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:15, and the V L The region contains the amino acid sequence shown in SEQ ID NO:18; or Applicable V H The region includes the amino acid sequence shown in SEQ ID NO:15, and the V L The region contains the amino acid sequence shown in SEQ ID NO:19. A conjugate according to any of the embodiments 1 to 7. 9. A conjugate according to any of embodiments 1 to 8, wherein the antibody or antigen-binding fragment comprises MA251, 7G7B6 or its antigen-binding portion. 10. A conjugate according to any of embodiments 1 to 9, which exhibits one or more Fc-mediated effector functions. 11. Lacks Fc-mediated effector functionality. It exhibits substantially reduced Fc-mediated effector functionality, or It does not demonstrate any actual Fc-mediated effector function. A conjugate according to any of the embodiments 1 to 9. 12. The conjugate of embodiment 11, wherein the activated conjugate is capable of killing cells in the absence of substantial Fc-mediated effector function. 13. A conjugate according to any of embodiments 10 to 12, wherein the Fc-mediated effector function is selected from one or more of antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cell-mediated cytotoxicity (CDC). 14. A conjugate according to any of embodiments 1 to 13, having at least two modes of action for causing cell death when activated. 15. A conjugate according to aspect 14, wherein at least one of the two modes of action is ADCC independent. 16. A conjugate according to any of embodiments 1 to 15, wherein the activated conjugate exhibits at least one mode of cell death or tumor inhibition that is not present in non-conjugated antibodies. 17. A conjugate according to any of embodiments 1 to 16, comprising an IgG1 Fc region or IgG1 isotype, an IgG2 Fc region or IgG2 isotype, an IgG3 Fc region or IgG3 isotype, or an IgG4 Fc region or IgG4 isotype. 18. A conjugate according to any of embodiments 1 to 17, wherein the antibody or antibody-binding fragment comprises an IgG1 Fc region or an IgG1 isotype. 19. The conjugate of embodiment 18, wherein the IgG1 Fc region does not exhibit enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) effector function. 20. A conjugate according to any of embodiments 1 to 17, wherein the antibody or antibody-binding fragment comprises an IgG2 Fc region or an IgG2 isotype. 21. A conjugate according to embodiment 20, wherein the IgG2 Fc region includes substitutions that reduce or suppress ADCC effector function. 22. The conjugate of aspect 21, wherein the substitution is a substitution of asparagine to glutamine in the Fc region at the position corresponding to 297 in EU numbering (N297Q). 23. A conjugate according to any of embodiments 1 to 22, wherein the antibody or antigen-binding fragment is a human antibody or human antigen-binding fragment, a chimeric antibody or chimeric antigen-binding fragment, or a humanized antibody or humanized antigen-binding fragment. 24. A conjugate according to any of embodiments 1 to 23, wherein the antibody or antigen-binding fragment comprises the Fc region and / or human antibody framework region of a human immunoglobulin. 25. (a) A step of administering a conjugate according to any of embodiments 1 to 24 to a subject, and (b) Applying a 25 J / cm² dose to the target area within the target area at wavelengths ranging from 600 nm or approximately 600 nm to 850 nm or approximately 850 nm. 2 Alternatively, approximately 25 J / cm² 2 From 400 J / cm² 2 Alternatively, approximately 400 J / cm² 2 The process involves irradiating the fiber with a dose ranging from 2 J / cm of fiber length or approximately 2 J / cm of fiber length to 500 J / cm of fiber length or approximately 500 J / cm of fiber length, thereby activating the conjugate. A method for treating a tumor or lesion in a subject, including, This reduces or inhibits the growth, volume, or size of the tumor or lesion. The aforementioned method. 26. (a) A step of administering to a subject a conjugate comprising an antibody or antigen-binding fragment that specifically binds to CD25 without substantially blocking or interfering with IL-2 signaling and a Si-phthalocyanine dye. (b) Applying a 25 J / cm² dose to the target area within the target, with wavelengths ranging from 600 nm or approximately 600 nm to 850 nm or approximately 850 nm. 2 Alternatively, approximately 25 J / cm² 2 From 400 J / cm² 2Alternatively, approximately 400 J / cm² 2 The process involves irradiating the fiber with a dose ranging from 2 J / cm of fiber length or approximately 2 J / cm of fiber length to 500 J / cm of fiber length or approximately 500 J / cm of fiber length, thereby activating the conjugate. A method for treating a tumor or lesion in a subject, including, This reduces or inhibits the growth, volume, or size of the tumor or lesion. The aforementioned method. 27. The method according to aspect 25 or 26, wherein the tumor or lesion being treated, or the tumor microenvironment (TME) of the tumor or lesion being treated, contains reduced levels of immune effector cells. 28. The method according to embodiment 26 or 27, wherein the Si-phthalocyanine dye is IR700 and the irradiation is carried out at a wavelength of 690 nm ± 20 nm. 29. Si-phthalocyanine dyes, formula (I) A method according to embodiment 26 or 27, comprising TIFF0007948938000023.tif71128, or a salt thereof, stereoisomer, or tautomer thereof, wherein the irradiation is carried out at a wavelength of 660 nm ± 50 nm. 30. Any method according to embodiment 27 to 29, wherein the immune effector cells are selected from one or more of macrophages, natural killer (NK) cells, neutrophils, and eosinophils. 31. Any method of embodiment 25 to 30, wherein the target site is irradiated within approximately 24 ± 4 hours after administration of the conjugate. 32. The target area is 50 mW / cm². 2 Or approximately 50 mW / cm² 2 From 200mW / cm 2 Or approximately 200 mW / cm² 2 A method of any of embodiments 25 to 31, wherein the light is irradiated with an optical power up to [a certain value]. 33. Any method according to embodiments 25 to 31, wherein the target area is irradiated with an optical power ranging from 100 mW / cm fiber length or approximately 100 mW / cm fiber length to 500 mW / cm fiber length or approximately 500 mW / cm fiber length. 34. Any method according to embodiments 25 to 33, wherein the target site is irradiated for a period of time from 120 seconds or approximately 120 seconds to 600 seconds or approximately 600 seconds. 35. Any method according to aspects 25 to 34, wherein the tumor or lesion is resistant to or unresponsive to immune checkpoint inhibitor therapy. 36. Any method according to embodiment 25 to 34, wherein the tumor or lesion has a reduced response or is unresponsive to a non-conjugate antibody. 37. Any method according to embodiments 26 to 36, wherein the conjugate exhibits one or more Fc-mediated effector functions. 38. Any method of embodiments 26 to 36, wherein the conjugate lacks Fc-mediated effector function, exhibits substantially reduced Fc-mediated effector function, or exhibits substantially no Fc-mediated effector function. 39. The method of embodiment 38, wherein the activated conjugate is capable of killing cells in the absence of substantial Fc-mediated effector function. 40. A method according to any one of embodiments 37 to 39, wherein the Fc-mediated effector function is selected from one or more of antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cell-mediated cytotoxicity (CDC). 41. Any method according to embodiment 26 to 40, wherein the conjugate includes an IgG1 Fc region or an IgG1 isotype, an IgG2 Fc region or an IgG2 isotype, an IgG3 Fc region or an IgG3 isotype, or an IgG4 Fc region or an IgG4 isotype. 42. A method according to any of embodiments 26 to 41, wherein the antibody or antibody-conjugated fragment comprises an IgG1 Fc region or an IgG1 isotype. 43. The method of embodiment 42, wherein the IgG1 Fc region is not enhanced with respect to ADCC effector function. 44. Any method according to embodiment 26 to 43, wherein the antibody or antibody-conjugated fragment comprises an IgG2 Fc region or an IgG2 isotype. 45. The method of embodiment 44, comprising substitution of an IgG2 Fc region that reduces or suppresses ADCC effector function. 46. The method of embodiment 45, wherein the substitution is a substitution of asparagine to glutamine in the Fc region at the position corresponding to EU number 297 (N297Q). 47. Any method of embodiment 25 to 46, further comprising the step of administering an immune checkpoint inhibitor therapy after administration of a conjugate. 48. The method of aspect 47, wherein immune checkpoint inhibitor therapy is administered 1, 2, 3, 4, 5, 6, 7 days, 1 week, 2 weeks, or 3 weeks after administration of the conjugate. 49. The method according to aspect 47 or 48, wherein immune checkpoint inhibitor therapy is administered 1, 2, 3, 4, 5, 6, 7, 1 week, 2 weeks, or 3 weeks after irradiation. 50. Any of the methods described in 47 to 49, wherein immune checkpoint inhibitor therapy is administered more than once after administration of the conjugate. 51. Any method according to embodiment 47 to 50, wherein the immune checkpoint inhibitor therapy comprises a PD-1 inhibitor, a PD-L1 inhibitor, or a CTLA-4 inhibitor. 52. PD-1 inhibitors include pembrolizumab (MK-3475, KEYTRUDA; lambrolizumab), nivolumab (OPDIVO), semiprimab (LIBTAYO), tripalimab (JS001), HX008, SG001, GLS-010, dostallimab (TSR-042), tislerizumab (BGB-A317), cetrelimab (JNJ-63723283), Pizilizumab (CT-011), Genolimuzumab (APL-501, GB226), BCD-100, Semiprimab (REGN2810), F520, Syntilimab (IBI308), CS1003, LZM009, Camrelizumab (SHR-1210), SCT-I10A, MGA012, AK105, PF-06801591, AMP-224, AB122, AMG The method according to embodiment 51, wherein the anti-PD-1 antibody is selected from 404, BI 754091, HLX10, JTX-4014, AMP-514 (MEDI0680), Sym021, MGD019, MGD013, AK104, XmAb20717, RO7121661, CX-188, spartalizumab, BCD-217, HX009, IBI308, PDR001, REGN2810, TSR-042 (ANB011), or their antigen-binding fragments or any combination thereof. 53. Any method according to any of embodiments 25 to 52, wherein a regulatory T cell (Treg) population in a tumor or lesion or in the tumor microenvironment is reduced as a result of the method. 54. Any method according to embodiments 25 to 53, wherein the reduction or inhibition includes one or more of an increase of less than 20% in tumor volume or tumor dimensions, or a reduction in tumor volume, tumor dimensions or tumor mass, or a reduction in the number of tumor cells. 55. Any method of embodiments 25 to 54, wherein tumor or lesion growth, volume, or size is inhibited or reduced to a greater extent compared to a method using a conjugate comprising an antibody or antigen-binding fragment that specifically binds to CD25 and substantially blocks or interferes with IL-2 signaling. 56. Any method according to embodiments 25 to 55 that improves the survival of the subject. 57. Any method according to any of embodiments 25 to 56, wherein the subject includes a second tumor or a secondary population of tumor cells, and the growth, volume, or dimensions of the second tumor or secondary population of tumor cells are reduced or inhibited as a result of the method. 58. The method of aspect 57, wherein a second tumor or secondary population of tumor cells has not been irradiated. [Examples]
[0194] IX. Examples The following examples are included for illustrative purposes only and are not intended to limit the scope of the present invention.
[0195] Example 1 : Generation of IRDye 700 conjugate anti-CD25 antibody This example describes a method for preparing conjugates containing exemplary phthalocyanine dye IRDye 700DX (IR700) linked to mouse IgG1 and IgG2a isotype anti-CD25 antibodies PC61 (exemplary IL-2 blocking anti-CD25 antibody) and 7D4 (exemplary IL-2 non-blocking anti-CD25 antibody), and for producing PC61-mIgG1-IR700, PC61-mIgG2a-IR700, 7D4-mIgG1-IR700, and 7D4-mIgG2a-IR700. Table 2 shows the SEQ ID NOs corresponding to the amino acid sequences of the variable heavy chain (VH), constant heavy chain (CH1-CH3), variable light chain (VL), and constant light chain (CL) of the antibodies.
[0196] (Table 2) TIFF0007948938000024.tif33167
[0197] Rat monoclonal antibodies (mAbs) PC61 or 7D4 against mouse CD25, of isotype mIgG1 or mIgG2a, were incubated in 0.1 mol / L Na2HPO4 (pH 8.5) with IRDye 700DX NHS ester (IR700; LI-COR Bioscience, Lincoln, NE) (52.1–71.9 μg [27.2–36.8 nmol], 1 mg [6.8 nmol] of antibody each in 5 mmol / L DMSO) at room temperature for 30–120 minutes. Conjugates were prepared as batches of antibody ranging from 50–182 mg. Then, 1 mol / L C2H5NO2 (pH 9.0) was added to the mixture at room temperature for 2–16 hours until the target concentration of 20 mmol / L was reached. The buffer of the mixture was replaced using an Amicon centrifugal spin filter (30 kD; Millipore Sigma). Protein concentrations and dye-to-antibody ratios (DARs) were determined by measuring absorption at 280 nm and 690 nm using analytical size exclusion (SEC-HPLC). Protein concentrations were measured using the 280 nm absorption, corrected for the effect of dye absorption at 690 nm. The average DAR was calculated as the ratio of peak areas at the measured wavelengths. The average number of IR700 per mAb (PC61 or 7D4) was approximately 3.
[0198] The purity of PC61-IR700 and 7D4-IR700 conjugates was confirmed by analytical size exclusion HPLC (SE-HPLC). SE-HPLC was performed using an Agilent 1100 HPLC system (Santa Clara, CA) equipped with a PDA detector controlled by Chemstation software. SE chromatography was performed using a Shodex KW-803 column (New York, NY) with phosphate-buffered saline (PBS) at elution at 1.0 mL / min for 20 minutes. The conjugate preparations showed strong association and did not contain any mAb aggregates detectable by SE-HPLC.
[0199] To determine the in vitro binding properties of the IR700 conjugate, the Indo-Gen procedure is used for the conjugate. 125 I-labeling was performed. Minimal mAb loss was observed with IR700 conjugation. Immunoreactivity assays were performed. Briefly, after trypsin treatment, 2 × 10⁻⁶ 6 The tumor cells were resuspended in PBS containing 1% bovine serum albumin (BSA). 125 I-PC61-IR700 (1mCi, 0.2μg) or 125 I-7D4-IR700 (1 mCi, 0.2 μg) was added, and the cells were incubated on ice for 1 hour. The cells were washed, pelletized, the supernatant was decanted, and the cells were counted using a 2470 Wizard gamma counter (Perkin Elmer, Shelton, CT). Nonspecific binding to cells was investigated under conditions of excess unlabeled antibody (200 μg of unconjugated unlabeled mAb).
[0200] Example 2 : Photoimmunotherapy (PIT) using IL-2 non-blocking anti-CD25 conjugates is more effective than IL-2 blocking PIT in inhibiting tumor growth. This example compares the activity of exemplary IL-2 non-blocking anti-CD25-IR700 conjugates and exemplary IL-2 blocking anti-CD25-IR700 conjugates against primary colon cancer tumors with and without photoirradiation.
[0201] 1 × 10¹⁶ BALB / c mice were placed in the right posterior ventral region of 6-8 week old BALB / c mice. 6 Individual CT26 mouse colon cancer cells were subcutaneously inoculated. The allogeneic transplanted tumor was approximately 150 mm. 3When the tumors had grown to a certain size (approximately 6 days after tumor transplantation), mice were administered either saline (100 μL; n=12; control), an IL-2 non-blocking anti-CD25 antibody 7D4-mIgG1-IR700 conjugate (7D4-IR700; 100 μg; n=24) produced as described in Example 1 above, or an IL-2 blocking anti-CD25 antibody PC61-IgG1-IR700 conjugate (PC61-IR700; 100 μg; n=24) by retroorbital (RO) injection. Twenty-four hours after conjugate administration, the tumors in half of the conjugate-treated mice were injected at 690 nm with 100 J / cm² of injection. 2 The mice were irradiated with the specified dose (photoimmunotherapy (PIT) group). Tumor growth was measured every 2-3 days for all mice, and tumor volume was calculated using the formula: Tumor volume = (short diameter × short diameter) × long diameter / 2. Mouse survival was also recorded over time.
[0202] The mean tumor growth and individual tumor growth for each treatment group are shown in Figures 1 and 2A-2E, respectively. In mice treated with an exemplary IL-2 non-blocking anti-CD25-IR700 conjugate in combination with irradiation (7D4-IR700 PIT; black triangle, dashed line), the mean tumor growth was substantially inhibited compared to the mean tumor growth inhibition in control mice treated with saline (white circle) or 7D4-IR700 conjugate alone without irradiation (black triangle, solid line). Mice treated with 7D4-IR700 conjugate alone without irradiation also showed reduced tumor growth compared to saline control mice. In contrast, the mean tumor growth in mice treated with IL-2 blocking anti-CD25-IR700 conjugate alone (PC61-IR700 conjugate) without irradiation was indistinguishable from that of saline control mice (black square, white circle against solid line). In mice administered with IL-2-blocking anti-CD25-IR700 conjugate and irradiation (PC61-IR700 PIT; black square, dashed line), tumor growth reduction was greater than that observed with IL-2-non-blocking anti-CD25 conjugate alone, but smaller than that observed with IL-2-non-blocking anti-CD25 PIT. As shown in Figures 2A-2E, which plot the growth of individual tumors, 7 out of 12 mice treated with IL-2 non-blocking anti-CD25 PIT (7D4-IR700 PIT) achieved complete remission (CR) (Figure 2D), while 4 out of 12 mice treated with IL-2 non-blocking anti-CD25 conjugate alone or IL-2 blocking anti-CD25 PIT achieved CR (Figures 2B and 2E, respectively), 1 out of 12 mice treated with IL-2 blocking anti-CD25 conjugate alone achieved CR (Figure 2C), and 0 out of 12 control mice treated with saline achieved CR (Figure 2A).Consistent with these results, as shown in Figure 3, mice administered with IL-2 non-blocking anti-CD25 PIT (7D4-IR700 PIT) showed the highest survival rate (black triangle, dashed line), followed by mice administered with IL-2 blocking anti-CD25 PIT (PC61-IR700 PIT; black square, dashed line), IL-2 non-blocking anti-CD25 conjugate alone (no irradiation) (7D4-IR700 conjugate; black triangle, solid line), IL-2 blocking anti-CD25 conjugate alone (PC61-IR700 conjugate; black square, solid line), and a saline control (saline; white circle, solid line). In summary, these results indicate that IL-2 non-blocking anti-CD25 PIT is more effective than IL-2 blocking anti-CD25 PIT in inhibiting tumor growth and promoting survival in tumor-bearing mice, and is more effective than IL-2 non-blocking anti-CD25 conjugate alone.
[0203] Example 3 : IL-2 non-blocking anti-CD25 photoimmunotherapy (PIT) and anti-PD-1 antibodies synergistically inhibit tumor growth in vivo. This example describes the synergistic inhibitory effect on tumor growth in an anti-PD-1 resistant mouse tumor model of exemplary IL-2 non-blocking anti-CD25-IR700 photoimmunotherapy (PIT) in combination with an anti-PD-1 antibody, compared to treatment with a naked (non-conjugated) anti-CD25 antibody.
[0204] 5 × 10¹⁴ granules were placed in the right posterior flank of immunocompetent BALB / c mice aged 6-8 weeks. 5 Individual MCA205 mouse fibrosarcoma cells were subcutaneously inoculated (day 0). The allogeneic transplanted tumor was approximately 150 mm. 3When the tumors had grown to a certain size (day 7), the mice were administered saline (group 1), anti-PD-1 antibody (group 2), naked IL-2 non-blocking 7D4-mIgG2a antibody (group 3), 7D4-mIgG2a-IR700 conjugate (group 4), naked 7D4-mIgG2a antibody and anti-PD-1 antibody (group 5), or 7D4-mIgG2a-IR700 conjugate and anti-PD-1 antibody (group 6), as detailed in Table 3. The conjugate was generated as described in Example 1. Saline, antibody, and conjugate were administered via retroorbital (RO) injection. As shown in Table 3, 24 hours after conjugate administration (day 8), the tumors in half of the mice administered with the 7D4-mIgG2a-IR700 conjugate were injected at 690 nm with 200 J / cm². 2 The mice were irradiated with the specified dose (photoimmunotherapy (PIT) group). On day 7, mice in groups 2, 5, and 6 were administered anti-PD-1 antibody, and repeated doses were given three times a week throughout the study. Tumor growth was measured every 2-3 days for all mice, and tumor volume was calculated using the formula: Tumor volume = (short diameter × short diameter) × long diameter / 2. Survival was also recorded.
[0205] (Table 3) Treatment Groups TIFF0007948938000025.tif56167
[0206] The mean tumor growth and individual tumor growth for each treatment group are shown in Figures 4A-4B and 5A-5E, respectively. Figure 6 shows survival. As shown in Figures 4A and 5A, 5D, 5B, and 5E, administration of saline (Figure 4A; black circles, solid line and Figure 5A), anti-PD-1 antibody alone (Figure 4A; white circles, dashed line and Figure 5D), naked 7D4-mIgG2a antibody (Figure 4A; black squares, solid line and Figure 5B), or naked 7D4-mIgG2a antibody and anti-PD-1 antibody (Figure 4A; white squares, dashed line and Figure 5E) was ineffective in reducing tumor growth, and no mice achieved complete response (CR) in any of these treatment groups. These results were consistent with the survival results, where only 7D4-mIgG2a antibody treatment improved survival (Figure 6; black squares, solid line). These results indicate that MCA205 cells are resistant to anti-PD-1 immunotherapy and IL-2 non-blocking anti-CD25 antibody immunotherapy, either as monotherapy or in combination. In contrast, 7D4-mIgG2a-IR700 PIT substantially reduced tumor growth compared to saline control (Figure 4B; black triangles, solid lines and Figure 5C), achieving complete response (CR) in 3 out of 10 mice and substantially improving survival (Figure 6; black triangles, dashed lines). The combination of 7D4-mIgG2a-IR700 PIT and anti-PD-1 further inhibited tumor growth (Figure 4B; white triangles, dashed lines and Figure 5E), achieving CR in 7 out of 10 mice and resulting in 100% survival (Figure 6; white triangles, dashed lines). In summary, these results indicate that IL-2 non-blocking anti-CD25 PIT is more effective than naked IL-2 non-blocking anti-CD25 antibody alone in inhibiting tumor growth and promoting survival. Furthermore, IL-2 non-blocking anti-CD25 PIT acted synergistically with anti-PD-1 treatment, resulting in even greater inhibition of tumor growth compared to either monotherapy alone. IL-2 non-blocking anti-CD25 PIT in combination with anti-PD-1 treatment was more effective than naked IL-2 non-blocking anti-CD25 antibody treatment, with or without anti-PD-1 treatment, in inhibiting tumor growth and promoting survival. In this anti-PD-1 resistant tumor model, treatment with naked IL-2 non-blocking anti-CD25 antibody was ineffective in reducing tumor growth.In addition to treatment with a naked IL-2 non-blocking anti-CD25 antibody, administration of an anti-PD-1 antibody had no substantial effect on inhibiting tumor growth or promoting survival in this anti-PD-1 resistant model.
[0207] Example 4 : Photoimmunotherapy (PIT) using IL-2 non-blocking anti-CD25 conjugates is more effective than IL-2 blocking PIT in inducing a systemic immune response. In this example, we compare the effects (abscopal effect) of photoimmunotherapy (PIT) using a conjugate with an IL-2 blocking anti-CD25 antibody as the targeting molecule with PIT using a conjugate with an IL-2 non-blocking anti-CD25 antibody as the targeting molecule on directly treated tumors and unirradiated, remotely located tumors.
[0208] 1 × 10¹⁶ posterior ventral regions on both sides of immunocompetent BALB / c mice 6 Individual MCA-205 mouse fibrosarcoma cells were subcutaneously inoculated. The bilateral allogeneic transplanted tumors had a volume of approximately 150 mm². 3 When the tumor cells had grown (5 days after inoculation), mice were intravenously administered either an exemplary IL-2 blocking anti-CD25 antibody conjugated with IR700 (PC61-mIgG1-IR700; 100 μg) or an exemplary IL-2 non-blocking anti-CD25 antibody conjugated with IR700 (7D4-mIgG1-IR700; 100 μg), as produced as described in Example 1 above, in 100 μL of saline. Twenty-four hours after administration of the conjugate, the tumors in the right flank of half of the animals administered PC61-IR700 or 7D4-IR700 were injected at 690 nm with 200 J / cm². 2 The tumor was irradiated with a dose, while the tumor in the left flank was shielded from irradiation. The growth of the irradiated tumor (target tumor) and the unirradiated tumor (distal tumor) was observed over time, and the tumor volume was calculated using the formula: Tumor volume = (short diameter × long diameter) × height / 2.
[0209] As shown in Figures 7A and 7B, tumors in saline-treated animals showed rapid growth. Tumor growth in mice treated with IL-2-blocking PC61-IR700 conjugate alone (without irradiation) was indistinguishable from that observed in saline-controlled animals (Figure 7A; white circles), while tumor growth in animals treated with PC61-IR700 PIT showed substantial inhibition of tumor growth in irradiated tumors (Figure 7A; black circles). Tumor growth in mice treated with IL-2-non-blocking 7D4-IR700 conjugate alone (without irradiation) showed slightly reduced tumor growth compared to saline controls (Figure 7B; white squares). Tumors treated with 7D4-IR700 PIT showed almost complete suppression of tumor growth in tumors irradiated after treatment (Figure 7B; black squares).
[0210] In mice treated with saline (Figures 8A and 8B; white triangles) and mice treated with IL-2-blocking PC61-IR700 conjugate alone (Figure 8A; white circles), non-irradiated tumors distal to the irradiation site (distal tumors) showed continuous tumor growth. Non-irradiated distal tumors in mice treated with PC61 PIT (Figure 8A; black circles) or IL-2-non-blocking 7D4 conjugate alone (no irradiation) (Figure 8B; white squares) showed a small reduction in tumor growth compared to saline controls. Non-irradiated distal tumors in mice treated with IL-2-non-blocking 7D4-IR700 conjugate PIT showed approximately a 50% reduction in tumor growth compared to saline controls (Figure 8B; black squares). The results indicate that treatment with anti-CD25 PIT, particularly IL-2-non-blocking anti-CD25 PIT, is effective in reducing tumor growth in irradiated and non-irradiated distal tumor lesions. Based on the abscopal effect (i.e., inhibition of tumor growth in distal, non-irradiated lesions), these effects indicate that IL-2 non-blocking anti-CD25 PITs are more effective than IL-2 blocking anti-CD25 PITs in inducing a systemic immune response.
[0211] Furthermore, the results demonstrate that IL-2 non-blocking anti-CD25 PIT treatment is more effective than conjugate treatment alone without irradiation in inhibiting tumor growth in irradiated and non-irradiated distal lesions.
[0212] Example 5 : Antibody-dependent cell-mediated cytotoxicity (ADCC) of IL-2 non-blocking anti-CD25 antibodies and corresponding IL-2 non-blocking anti-CD25 conjugates. In this example, the antibody-dependent cell-mediated cytotoxicity (ADCC) activity of exemplary naked (non-conjugated) IL-2 non-blocking anti-CD25 antibodies and conjugates containing IL-2 non-blocking anti-CD25 antibodies and the phthalocyanine dye IR700 was evaluated.
[0213] ADCC activity for naked IL-2 non-blocking anti-CD25 antibody (7D4-mIgG2a) and IL-2 non-blocking anti-CD25-IR700 conjugate (7D4-mIgG2a-IR700) produced as described in Example 1 above was measured using the ADCC Reporter Bioassay Kit (Promega) substantially as described in the vendor's protocol. Briefly, target HT-2 cells were seeded at a density of 25,000 cells / well in 96-well white-walled plates. The following day, the medium was replaced with 25 μL of ADCC Assay Buffer, followed by 25 μL of nine sequentially diluted concentrations of 7D4-mIgG2a antibody or 7D4-mIgG2a-IR700 conjugate at concentrations three times higher than the final concentration. Sequential dilutions were prepared starting at 6 μg / mL (1×=2 μg / mL). ADCC response induction was initiated by adding 25 μL (75,000 cells) of effector cells to achieve an effector-to-target cell ratio of 3:1. The mixture was incubated at 37°C for 6 hours. To quantify the ADCC response, the plate was brought to room temperature, and 75 μL of Bio-Glo luciferase assay reagent was added to the cell-containing wells and three surrounding cell-free wells for background determination. After incubation at ambient temperature for 20 minutes, luminescence was read using a Tecan Spark multiplate reader (Tecan Life Sciences). To analyze the data, background was subtracted from the cell-free wells, and the data were fitted to a four-variable nonlinear curve-fitting algorithm (GraphPad Prism software).
[0214] The results are shown in Figure 9. Both the naked antibody and the conjugate showed a dose-dependent increase in ADCC activity. Naked 7D4-mIgG2a showed a dose-dependent increase of 36.14 EC. 50 (R 2 7D4-mIgG2a-IR700 conjugate with :0.9949 has 23.85 EC 50 (R 2 The naked 7D4-mIgG2a antibody showed strong ADCC potency and efficacy at 0.9896, and a higher saturation point was observed compared to the 7D4-mIgG2a-IR700 conjugate. These results indicate that the IR700 conjugate exhibits weaker ADCC activity compared to the naked antibody.
[0215] Example 6 : IL-2 non-blocking anti-CD25 photoimmunotherapy (PIT) does not require antibody-dependent cell-mediated cytotoxicity (ADCC) / antibody-dependent cell-mediated phagocytosis (ADCP) for antitumor activity. This example evaluates the effects of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) on the antitumor activity of treatment with exemplary IL-2 non-blocking anti-CD25 antibodies and IL-2 non-blocking anti-CD25 photoimmunotherapy (PIT).
[0216] The antitumor activity of IL-2 non-blocking anti-CD25 antibodies with an mIgG2a scaffold that are ADCC / ADCP-compatible and ADCC / ADCP-null, as well as IL-2 non-blocking anti-CD25 conjugates with and without irradiation of the mIgG1 scaffold, was compared using mouse primary colon cancer tumors. The mIgG2a isotype has a higher binding affinity to the mouse Fc gamma receptor than the mIgG1 isotype and exhibits higher levels of ADCC / ADCP activity than the mIgG1 isotype (Stewart et al., (2014) J. Immunotherapy Cancer 2, 29). The substitution of asparagine to glutamine in the Fc region at the position corresponding to EU number 297 (N297Q) inhibits the interaction between the Fc region and the Fc gamma receptor, resulting in null ADCC / ADCP activity for the IgG2a isotype.
[0217] 1 × 10¹⁶ BALB / c mice were placed in the right posterior ventral region of 6-8 week old BALB / c mice. 6Individual CT26 mouse colon cancer cells were subcutaneously inoculated. The allogeneic transplanted tumor was approximately 150 mm. 3 When the tumors had grown to a certain size (approximately 6 days after tumor transplantation), mice were administered either physiological saline (100 μL; n=12; control) or the IL-2 non-blocking anti-CD25 antibody 7D4-mIgG1-IR700 conjugate (7D4-IR700; 100 μg; n=24) produced as described in Example 1 above, by retroorbital (RO) injection; or the naked (unconjugated) IL-2 non-blocking anti-CD25 antibody 7D4-mIgG2a (10 mg / kg; n=11) or the 7D4-mIgG2a-ADCC / ADCP null (7D4-mIgG2a-N297Q; 10 mg / kg; n=12) by intraperitoneal (IP) administration. Twenty-four hours after administration of the antibody or conjugate, the tumors in half of the conjugate-treated mice were injected at 690 nm with 100 J / cm² of water. 2 The mice were irradiated with the specified dose (photoimmunotherapy (PIT) group). Tumor growth was measured every 2-3 days for all mice, and tumor volume was calculated using the formula: Tumor volume = (short diameter × short diameter) × long diameter / 2. Mouse survival was also recorded over time.
[0218] The mean tumor growth and individual tumor growth for each treatment group are shown in Figures 10 and 11A-11E, respectively. Mice treated with the naked 7D4-mIgG2a antibody showed substantial inhibition of tumor growth compared to saline control mice (Figure 10; white circles against black squares), and 10 out of 11 mice achieved complete remission (Figure 11D). This effect was almost completely suppressed in mice treated with 7D4-mIgG2a-ADCC / ADCP null (the same naked antibody with respect to the ADCC null mutant mIgG2a skeleton; Figure 10; white squares and Figure 11B), indicating that the tumor growth inhibition observed for 7D4-mIgG2a was dependent on ADCC activity.
[0219] Mice administered with the 7D4-mIgG1-IR700 conjugate without irradiation showed mean tumor growth similar to that of unconjugated 7D4-mIgG2a antibodies lacking ADCC / ADCP activity (Figure 10; black triangles, solid line (conjugate) vs. white squares, solid line (ADCC / ADCP null antibody)). However, compared to 1 in 12 mice treated with 7D4-mIgG2a-N297Q (ADCC null) (Figure 11B), 4 out of 12 mice treated with the 7D4-mIgG1-IR700 conjugate achieved complete remission (Figure 11C). Since mIgG1 antibodies still exhibit low levels of ADCC / ADCP activity, this result further supports the idea that tumor growth inhibition depends on ADCC / ADCP activity. However, mice irradiated after administration of 7D4-mIgG1-IR700 (7D4-mIgG1-IR700+PIT) showed substantially greater inhibition of tumor growth than the conjugate without irradiation (Figure 10, black triangles, dashed lines), and 7 out of 12 mice achieved complete response (CR) (Figure 11E).
[0220] As shown in Figure 12, the survival curves confirmed the observed inhibition of tumor growth. Consistent with the results of tumor growth inhibition, mice treated with an IL-2 non-blocking anti-CD25 mIgG2a antibody with increased ADCC activity showed the greatest survival (7D4-mIgG2a; black square), followed by IL-2 non-blocking anti-CD25 PIT (7D4-mIgG1-IR700 PIT; black triangle, dashed line), IL-2 non-blocking anti-CD25 conjugate alone (no irradiation) (7D4-mIgG1-IR700; black triangle, solid line), IL-2 blocking anti-CD25-IgG2a-ADCC / ADCP null antibody (7D4-mIgG2a-N297Q; white square), and the saline control (saline; white circle).
[0221] These results demonstrate that IL-2 non-blocking anti-CD25 PIT can effectively suppress tumor growth even when ADCC / ADCP activity is limited. Therefore, unlike non-conjugate IL-2 non-blocking anti-CD25 antibodies, ADCC / ADCP activity is not required for the efficacy of IL-2 non-blocking anti-CD25 PIT.
[0222] Example 7 : Efficacy of IL-2 non-blocking anti-CD25 antibody and IL-2 non-blocking anti-CD25 photoimmunotherapy (PIT) for cold tumors with and without anti-PD-1 antibody treatment. This embodiment describes the efficacy of naked (non-conjugate) IL-2 non-blocking anti-CD25 antibodies and IL-2 non-blocking anti-CD25 PITs against immune "cold" tumors, i.e., tumors characterized by low immunoreactivity (low levels and exhausted tumor-infiltrating lymphocytes (TILs), insufficient tumor antigen loading, and an immunosuppressive microenvironment). Cold tumors are characterized by poor response to immune checkpoint inhibitor therapy.
[0223] 1 x 10¹⁶ BALB / c mice (16-18g) were placed in the right posterior ventral region. 5 Individual 4T1 cells / mouse were subcutaneously inoculated. Allogeneic transplanted tumors were approximately 140 mm. 3 When the tumors grew to a certain volume (6 days after tumor cell inoculation), mice were administered either physiological saline (100 μL via intraperitoneal (IP) injection), 7D4-mIgG2a (200 μg via IP injection), or 7D4-mIgG2a-IR700 (100 μg via retroorbital injection). Half of each treatment group was also treated with the anti-PD-1 antibody RMP1-14 (10 mg / kg) three times a week (days 6, 9, 13, etc.). 24 hours after conjugate administration, the tumors in the group treated with 7D4-mIgG2a-IR700 were injected at 690 nm with 150 J / cm² of irradiated solution. 2 The tumors were irradiated with the following dose (7D4-mIgG2a PIT). Tumor growth (Figure 13) and survival (Figure 14) were measured over time.
[0224] 7D4-mIgG2a PIT, alone (white triangles) or in combination with anti-PD-1 (black triangles), substantially inhibited the growth of "cold" tumors compared to saline (white circles) or anti-PD-1 monotherapy (black circles) (Figure 13). 7D4-mIgG2a antibody, alone (white squares) or in combination with anti-PD-1 (black squares), had virtually no inhibitory effect on the growth of "cold" tumors (Figure 13). Survival curves were consistent with the antitumor effect of each treatment (Figure 14). These data support the finding that IL-2 non-blocking anti-CD25 PIT effectively inhibited the growth of cold tumors, while IL-2 non-blocking antibodies alone, with or without PD-1 treatment, had minimal effect on cold tumor growth.
[0225] The present invention should not be limited in scope by the embodiments disclosed herein, which are intended as one illustration of individual aspects of the invention, and all functional equivalents are within the scope of the invention. In addition to those described herein, various modifications to the compositions and methods of the invention will be apparent to those skilled in the art from the foregoing description and teachings, and these are also intended to be within the scope of the invention. Such modifications and other embodiments can be practiced without departing from the true scope and spirit of the invention.
[0226] array TIFF0007948938000026.tif237170TIFF0007948938000027.tif244170TIFF0007948938000028.tif178170
Claims
1. A pharmaceutical for use in a method of treating a tumor or lesion in a subject, comprising (i) an antibody or antigen-binding fragment that specifically binds to CD25 without substantially blocking or interfering with IL-2 signaling, and (ii) a Si-phthalocyanine dye, The method described above is (a) A step of administering the conjugate to a subject, (b) The target area within the target area is exposed to a 25 J / cm² wavelength from 600 nm or approximately 600 nm to 850 nm or approximately 850 nm. 2 Alternatively, approximately 25 J / cm² 2 From 400 J / cm² 2 Alternatively, approximately 400 J / cm² 2 The process involves irradiating the fiber with a dose ranging from 2 J / cm of fiber length or approximately 2 J / cm of fiber length to 500 J / cm of fiber length or approximately 500 J / cm of fiber length, thereby activating the conjugate. Includes, This reduces or inhibits the growth, volume, or size of the tumor or lesion. The aforementioned pharmaceutical.
2. The Si-phthalocyanine dye has the structure of formula (X): or a salt thereof, ionic form, stereoisomer, or tautomer, in the formula, X is And; Y is And; R 1 and R 2 Each of these is independently a substituted alkyl, a substituted cycloalkyl, a substituted cycloalkylalkyl, a substituted heterocyclyl, a substituted heterocyclylalkyl, a substituted aryl, a substituted aralkyl, a substituted heteroaryl, or a substituted heteroaralkyl; R 3 , R 4 or R 5 is selected from substituent (a) or substituent (b), where (a) R 3 is hydrogen, -L 3 -H, -L 3 -A or -L 3 -Z is; R 4 is, -L 4 -H, -(NH) m -L 4 -A, -(NH) m -L 4 -Z, -(O) m -L 4 -A or -(O) m -L 4 -Z is; R 5 is, -L 5 -H or -L 5 -A is; and (b) R 3 is, -L 3 -H or -L 3 -A is; R 4 is, -L 4 -H, -(NH) m -L 4 -A, or -(O) m -L 4 -A is the case; in that case, R 3 and R 4 It is connected by a bond, -L 4 -Forms heterocyclines substituted with A; and R 5 is, -L 5 -H or -L 5 -A is; However, R 3 , R 4 and R 5 At least one of them is a group containing A; A is a reactive group, or a protected form thereof, or a reactive form thereof, that can form a covalent bond with the thiol, hydroxyl, carboxyl, or amino group of the second part; R 6 and R 7 Each of these is independently a substituted alkyl, a substituted cycloalkyl, a substituted cycloalkylalkyl, a substituted heterocyclyl, a substituted heterocyclylalkyl, a substituted aryl, a substituted aralkyl, a substituted heteroaryl, or a substituted heteroaralkyl; R 8 , R 9 or R 10 This is selected from substituent (a) or substituent (b), in which case, (a) R 8 is hydrogen, -L 8 -H or -L 8 -Z is; R 9 is, -L 9 -H, -(NH) n -L 9 -Z or -(O) n -L 9 -Z is; R 10 is, -L 10 -Z is; and (b) R 8 and R 9 It is connected by a bond, -L 9 -Z is substituted, forming a heterocycline, R 10 is, -L 10 -H or -L 10 -Z is; However, R 8 , R 9 and R 10 At least one of them is a group containing Z; Z is a water-soluble group that may be substituted with A or L'-A; L 1 and L 2 Each of these is independently an optionally substituted alkylene, an optionally substituted heteroalkylene, an optionally substituted alkenylene, an optionally substituted heteroalkenylene, an optionally substituted cycloalkyl, or an optionally substituted heterocycline; L 3 , L 4 , L 5 , L 8 , L 9 and L 10 Each of these is independently a substituted alkylene, a substituted heteroalkylene, a substituted alkenylene, a substituted heteroalkenylene, a substituted cycloalkylene, a substituted heterocyclene, a substituted arylene, a substituted aralkylene, a substituted heteroaralkylene, or a substituted heteroarylene, where the carbon atoms of the alkylene, heteroalkylene, alkenylene, heteroalkenylene, cycloalkylene, heterocyclene, arylene, aralkylene, heteroaralkylene, or substituted heteroarylene may be further substituted with Z, and each nitrogen atom of the heteroalkylene or heteroalkenylene may be substituted with one or two L'-Z; L' is independently a substituted alkylene, a substituted heteroalkylene, a substituted alkenylene, a substituted heteroalkenylene, a substituted cycloalkylene, a substituted heterocyclene, a substituted arylene, a substituted aralkylene, a substituted heteroaralkylene, or a substituted heteroarylene; a is either 0 or 1; b is either 0 or 1; c is either 0 or 1; d is either 0 or 1; m is either 0 or 1; n is either 0 or 1; However, when b is 1, a is 0; When d is 1, then c is 0; If m is 1, then b is 1; and When n is 1, c is 1. A pharmaceutical product according to claim 1, comprising:
3. Si-phthalocyanine dyes are given by formula (I) The pharmaceutical product according to claim 1 or 2, comprising a salt thereof, a stereoisomer, or a tautomer thereof, wherein the irradiation is carried out at a wavelength of 660 nm ± 50 nm.
4. A pharmaceutical product as described in any one of items 1 to 3, wherein irradiation is performed at a wavelength of 690 nm ± 20 nm.
5. A pharmaceutical product according to any one of items 1 to 4, wherein the Si-phthalocyanine dye is IR700.
6. A pharmaceutical product according to any one of claims 1 to 5, wherein the tumor or lesion is resistant to or unresponsive to immune checkpoint inhibitor therapy.
7. The pharmaceutical product according to any one of claims 1 to 6, wherein the conjugate exhibits one or more Fc-mediated effector functions.
8. The pharmaceutical product according to any one of claims 1 to 6, wherein the conjugate lacks Fc-mediated effector function, exhibits substantially reduced Fc-mediated effector function, or exhibits substantially no Fc-mediated effector function.
9. The pharmaceutical product according to any one of claims 1 to 8, wherein the activated conjugate is capable of killing cells in the absence of substantial Fc-mediated effector function.
10. The pharmaceutical product according to any one of claims 7 to 9, wherein the Fc-mediated effector function is selected from one or more of antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), or complement-dependent cell-mediated cytotoxicity (CDC).
11. The pharmaceutical product according to any one of claims 1 to 10, wherein the conjugate has at least two modes of action for causing cell death when activated.
12. The pharmaceutical product according to claim 11, wherein at least one of the two modes of action is ADCC-independent.
13. The pharmaceutical product according to any one of claims 1 to 12, wherein the conjugate, when activated, exhibits at least one form of cell death or tumor inhibition not present in non-conjugated antibodies.
14. The pharmaceutical product according to any one of claims 1 to 13, wherein the conjugate comprises an IgG1 Fc region or an IgG1 isotype, an IgG2 Fc region or an IgG2 isotype, an IgG3 Fc region or an IgG3 isotype, or an IgG4 Fc region or an IgG4 isotype.
15. A pharmaceutical product according to any one of claims 1 to 14, wherein the antibody or antigen-binding fragment comprises an IgG1 Fc region or an IgG1 isotype.
16. The pharmaceutical product according to claim 15, wherein the IgG1 Fc region is not enhanced with respect to ADCC effector function.
17. A pharmaceutical product according to any one of claims 1 to 16, wherein the antibody or antigen-binding fragment comprises an IgG2 Fc region or an IgG2 isotype.
18. The pharmaceutical product according to claim 17, wherein the IgG2 Fc region comprises a substitution that reduces or inhibits the ADCC effector function.
19. The pharmaceutical product according to claim 18, wherein the substitution is a substitution of asparagine to glutamine in the Fc region at the position corresponding to EU number 297 (N297Q).
20. The pharmaceutical product according to any one of claims 1 to 19, wherein the antibody or antigen-binding fragment is a human antibody or human antigen-binding fragment, a chimeric antibody or chimeric antigen-binding fragment, or a humanized antibody or humanized antigen-binding fragment.
21. A pharmaceutical product according to any one of claims 1 to 20, comprising an antibody or antigen-binding fragment comprising the Fc region and / or human antibody framework region of a human immunoglobulin.
22. The pharmaceutical product according to any one of claims 1 to 21, wherein the method further comprises the step of administering an immune checkpoint inhibitor therapy after administration of a conjugate.
23. The pharmaceutical product according to any one of claims 1 to 22, wherein the treated tumor or lesion, or the tumor microenvironment (TME) of the treated tumor or lesion, contains reduced levels of immune effector cells.
24. The pharmaceutically acceptable agent according to claim 23, wherein the immune effector cells are selected from one or more of macrophages, natural killer (NK) cells, neutrophils, and eosinophils.
25. The pharmacopoeia according to claim 23 or 24, wherein the reduction or inhibition comprises one or more of an increase of less than 20% in tumor volume or tumor dimensions, or a reduction in tumor volume, tumor dimensions or tumor mass, or a reduction in the number of tumor cells.
26. The pharmacopoeia according to any one of claims 1 to 25, wherein the subject comprises a second tumor or secondary population of tumor cells, the growth, volume or dimensions of the second tumor or secondary population of tumor cells are reduced or inhibited as a result of the method, and the second tumor or secondary population of tumor cells has never been irradiated.
Citation Information
Patent Citations
Near-infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer
JP2018522055A
Phthalocyanine dye conjugates and storage methods thereof
JP2018528267A
Compositions, combinations and related methods for photoimmunotherapy
JP2018528268A
Therapeutic compositions and related methods for photoimmunotherapy
JP2020508323A
Fc-optimized anti-CD25 for tumor-specific cell depletion
JP2020514363A
